THE ROLE OF N6-METHYLADENOSINE IN HYPOXIA AND CELLULAR TRANSFORMATION by Fry, Nathaniel J.
 
 
THE ROLE OF N6-METHYLADENOSINE IN HYPOXIA AND CELLULAR 
TRANSFORMATION 
By 
Nathaniel J. Fry 
November, 2017 
Director Of Dissertation: Kyle Mansfield, PhD 
Major Department: Biochemistry and Molecular Biology 
 Cancer is a prevalent disease that affects millions of people each year across the 
globe. In an effort to find therapies to the many types of cancers, regulation of protein 
expression through transcription and translation pathways have been extensively 
studied. However, one area which has been often overlooked is the importance of post-
transcriptional regulation in protein output. The goal of this dissertation project has been 
to understand post-transcriptional regulation of mRNA during a cellular stress that all 
cancers must overcome in order to survive, oxygen deprivation. The lack of oxygen, 
termed hypoxia, is known to affect tumor growth and angiogenesis. Specifically, hypoxia 
affects the post-transcriptional regulation of mRNAs by increasing the stability of a 
subset of ischemia-related mRNAs, including VEGF. Multiple factors including RNA 
binding proteins and miRNAs have been identified to be important for the post-
transcriptional regulation of individual mRNAs, but mechanisms regulating global 
stability have not been elucidated. Recently, the mRNA modification, N6 
methyladenosine (m6A), has been shown to be involved in the post-transcriptional 
regulation processes of mRNA stability and promotion of translation. Therefore, I set out 
 
 
to investigate the effect of hypoxia on RNA m6A content.  My results show that hypoxic 
exposure leads to striking changes in the m6A content of mRNA in HEK-293T cells as 
well as immortalized and oncogenically transformed human mammary epithelial cells 
(HMECs). Using m6A mRNA immunoprecipitation, we identified a number of specific 
hypoxia related mRNAs, including Glut1 and c-Myc, which show increased m6A levels 
under hypoxic conditions. Many of these same mRNAs also exhibit increased mRNA 
stability revealed by metabolic labeling of RNA using 4sU. Furthermore, knockdown of 
the m6A-specific methyltransferases METTL3/14 blocked the hypoxic stabilization of 
these mRNA.  The increase in mRNA stability through m6A led to greater translational 
efficiency after recovery from the hypoxic stress. Overexpressing m6A in oncogenically 
transformed HMEC in normal oxygen conditions led to an increase in would healing, 
proliferation, and invasion abilities. Ultimately, the mRNA modification, m6A, led to 
phenotypic changes in a cancer cell, and it may be possible to manipulate this mRNA 
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Deoxyribonucleic acid (DNA) was discovered over 65 years ago as the molecule 
which stores genetic information within the cell. However, even though DNA is the 
storage unit for genetic material, the information needs to be translated into a usable 
form. To make this information functional, the DNA first needs to be transcribed into 
messenger ribonucleic acid (mRNA) and ultimately translated into protein. Regulation of 
these transcriptional, post-transcriptional, and translational steps plays a part in 
determining the functional protein output of the genetic material. Recently, it has been 
discovered that ribonucleic acid (RNA) modifications play an important role in post-
transcriptional and translational regulation. Many modifications, including N6-
methyladenosine (m6A), are found in all types of RNAs [1]. While the functions of a few 
of these modifications are known, the purpose of many other modifications have yet to 
be determined. However, early data suggests that many of these modifications are 
important in cell functionality and could play a role in diseases such as cancer.  
 There are over 100 known RNA modifications, and it is well established that 
ribosomal RNA (rRNA) and transfer RNA (tRNA) are rife with modifications. In fact, the 
most prevalent RNA modification, pseudouridine, is found mostly in rRNA and tRNA [2]. 
It is for this reason that modifications in these types of RNAs have been well studied. 
Many of these studied modifications in tRNA and rRNA have been revealed to lead to 
fine-tuning of their functions in translational efficiency [3]. Interestingly, to date, 
eukaryotic mRNA has been found to contain at least 13 modifications, including m6A, 5-
methylcytidine (m5C), and 7-methylguanosine (m7G) [1], but the function of many of 




 The m6A modification, found in most eukaryotes, is the most abundant 
modification in mRNA [4], and as such has been the focus of this project. In estimation, 
there are approximately three m6As per mRNA [5]. This modification has been shown to 
be important for the stability and translational efficiency of mRNA [6-11], and is involved 
in the pluripotency of stem cells in embryonic development [12-14] as well as the 
induction of a cancer stem cell phenotype in breast cancer cells [15, 16].  However, the 
m6A modification may function in other responses where rapid adaptation to fluctuating 
cellular environments is required.  
mRNA Methyltransferases 
The methyltransferase complex required for the formation of the m6A 
modification on mRNA consists of Methyltransferase like -3 and -14 (METTL3 and 
METTL14), as well as Wilms’ tumor associating protein (WTAP), and is responsible for 
methylating nascent pre-mRNA within the nucleus [17-21] (Figure 1.1). A couple of 
reports also suggest that other proteins, including KIAA1429, RBM15, and RBM15B are 
also a part of the methyltransferase complex as loss of these proteins decrease cellular 
m6A levels [22, 23]. However, unlike the other components of the methyltransferase 
complex, the involvement of these proteins in m6A has not been verified by authors 
outside of the original publications. METTL3 contains an S-adenosyl methionine (SAM) 
binding domain, and utilizes SAM as a substrate to methylate target adenosines on the 
nitrogen at the 6th carbon residue on mRNA that contain a DRACH m6A consensus 
sequence, often found in 3` UTR’s and around both start and stop codons [17, 24-27]. 
METTL14 lacks catalytic activity but participates in mRNA binding/targeting [28-30]. 





























Figure 1.1: m6A methylation reaction 
An adenosine is methylated at the N6 position replacing a hydrogen. The methyl group 
is shown in red on the second half of the figure. The methyltransferase complex 
consisting of METTL3, METTL14, and WTAP mediates this methylation. METTL3 
contains the SAM binding domain which catalyzes the donation of a methyl group from 
SAM and releasing S-adenosyl homocysteine (SAH). M6A methylation is reversible and 
demethylation occurs through FTO and ALKBH5 which are FeII and α-ketoglutarate 












speckle, and greatly enhances methyltransferase activity by bringing the 
methyltransferase to the pre-mRNA. However, WTAP is not ultimately required for 
methyltransferase activity [18, 34]. Although predominantly found in the nucleus, the 
methyltransferase complex, along with methyltransferase activity has been found within 
the cytoplasm [18, 35-38]. Interestingly, a recent study has shown that m6A methylation 
is not dynamic within the cytoplasm [21]. This study showed that the methylated 
adenosines in the nucleus were still methylated in the cytoplasm with no additionally 
methylated adenosines. This data suggests that m6A methylation is not dynamic in the 
cytoplasm.  
Demethylases 
m6A methylation of RNA is reversible and can be reportedly removed by 
alkylation repair homolog 5 (ALKBH5) and fat mass and obesity related protein (FTO) 
[39-48]. Together, these enzymes make up 2 of the 9 ALKB family members which are 
FeII and α-ketoglutarate (α-KG) dependent [31, 32] (Figure 1.1).  
Previously, FTO has been of major interest to the obesity field after it was 
identified that a single nucleotide polymorphism (SNP) in intron 1 of the FTO gene is 
associated with increased BMI and adiposity through genome wide association studies 
(GWAS) [49]. However, the link between FTO and obesity has recently been suggested 
to be indirect. An SNP in intron 1 of the FTO gene leads to the overexpression of two 
nearby genes, IRX3 and IRX5. The overexpression of these two genes then leads to a 
decrease in mitochondrial energy production and an increase in lipid accumulation [50, 




Even though ALKBH5 and FTO enzymes are closely related, the mechanism of 
m6A demethylation differ between the two. m6A demethylation through FTO yields two 
intermediate nucleotides, N6 -hydroxymethyladenosine (hm6A) and N6 -formyladenosine 
(fm6A), while demethylation through ALKBH5 yields no observable intermediates [44, 
52]. Because of this difference, it is possible that RNA binding proteins (RBPs) may 
interact with these intermediate RNA modifications during FTO mediated demethylation. 
Therefore, it may be important to determine which enzyme is active in the demethylation 
process in each model. A recent study has shown that FTO does not preferentially bind 
m6A, but rather N6,2′-O-dimethyladenosine (m6Am) [53]. In addition, previous reports 
showed that m6A sites were unaffected in FTO-deficient mice, and it is known that the 
antibodies used in early m6A mapping studies can bind m6Am as well [54, 55]. This 
new data suggests that FTO is not an m6A demethylase, but rather an m6Am 
demethylase. However, the many previous reports describing FTO as an m6A 
demethylase cannot all be discounted. 
RNA Binding Proteins 
m6A methylated mRNA is bound by RBPs that bind directly to the site of 
modification, including many members of the YTH family [9, 56, 57].  m6A also affects 
other RBPs that do not interact directly with the m6A site, but instead are affected by 
the RNA secondary structure caused by the modification [58, 59]. Interestingly, m6A 
affects double stranded RNA by rotating the face of the adenosine from the more 
energetically favorable “syn” confirmation to its less favorable “anti” confirmation [60]. 
This confirmation switching destabilizes the RNA duplex. However, m6A sites in single 




neighbors. Generally speaking, stretches of RNA containing the m6A modification tends 
to prefer a single stranded structure, however the overall structure of the RNA will be 
dependent on many m6A sites as well as other factors of RNA structure [60].  
The m6A modification has been shown to affect the binding of other RBPs 
including heterogeneous nuclear ribonucleoprotein (HNRNP)G and HNRNPC; in fact, 
over 13,000 m6A sites regulate RNA-HNRNPG interactions [58, 59]. In summary, the 
m6A modification not only directly interact with RBPs, but also indirectly regulate other 
RBPs through modifying RNA secondary structure which may lead to many downstream 
effects including changes in RNA stability and enhanced translational efficiency.    
While much is known about the mechanisms of m6A writing and erasing, the 
broader consequences of RNA methylation are still being investigated. It appears likely 
that the m6A binding proteins will ultimately determine the consequences of RNA 
methylation. This project has revealed that m6A can lead to stability of mRNA in hypoxic 
conditions [11].  However, in previous studies, m6A methylation has been shown to 
mark mRNA for degradation, mediated by YTHDF2 transport to P bodies where 
degradation of mRNA occurs through DCP1/DCP2 decapping and CCR4-NOT 
deadenylation [6, 9, 23, 40, 61]. Additionally, YTHDF1 has been reported to interact with 
initiation factors as well as enhance ribosomal loading in order to stimulate translational 
efficiency of m6A methylated mRNA thereby increasing translational output [10]. 
YTHDF3 and YTHDC2 have also been shown to promote translation of m6A methylated 
mRNA [62, 63], and it has been recently discovered that YTHDC2 is required for mouse 
spermatogenesis [63]. Another YTH family member that binds m6A, YTHDC1, interacts 






















Interact with initiation factors and enhance 
ribosomal loading to stimulate translational 
efficiency [10] 
YTHDF2 
Degradation of mRNA after transport of m6A mRNA 
to P-bodies 
[6, 9, 23, 40, 
61] 
YTHDF3 Promotes Translation [62] 
YTHDC1 Regulates mRNA splicing [57, 64] 




The interaction or competition between the YTH family of proteins (and other m6A 
binding proteins) is not yet understood as it has yet to be determined why binding of one 
takes precedence over another. However, we do know that YTHDF1, 2, 3, and YTHDC2 
are cytoplasmic, whereas YTHDC1 is nuclear [9, 56, 63, 64]. It may be possible that 
YTH binding is tissue or cell type specific, or, alternatively, YTH binding is competitive. It 
is possible that certain cell conditions or signaling will favor the binding of one YTH 
family member over another. Certainly, there is much more to understand about m6A 
binding proteins to fully grasp the overall consequences of RNA methylation.  
m6A in non-coding RNAs 
Even though m6A is prevalent in mRNA, it is also found in other types of RNAs 
including rRNA, long non-coding RNA (lncRNA), microRNA, and small nuclear RNA 
(snRNA) [65-68]. The m6A modification in microRNA has been reported to aid in pri-
microRNA processing through the RBP DGCR8 [69, 70]. In fact, the RBP HNRNPA2B1 
which interacts with DGCR8 is a nuclear reader of m6A. Loss of HNRNPA2B1 or Mettl3 
led to similar losses in microRNA production [70].  
The m6A modification is also found in snRNA’s including U6 snRNA. 
Interestingly, a completely different Mettl family protein, Mettl16, is responsible for the 
m6A methylation of U6 snRNA [71]. It seems likely that Mettl16 is a methyltransferase 
for many other RNA targets, and in fact unpublished data from our lab suggest that 
Mettl16 methylates 18S rRNA as well as a handful of mRNAs.  
Surprisingly, the m6A modification is only found in one location on both the 18S 




on 5 or 5.8S RNAs [72]. Interestingly, even though most rRNA modifications are highly 
conserved in eukaryotes, the m6A modification has not been detected in yeast rRNA 
[73]. Although the function of these modifications are not yet known, structure 
predictions informs us that the m6A sites are located in important areas for translational 
fidelity. The m6A site in the 18S rRNA is located at the top of helix 44 in the mRNA 
binding pocket, and the 28S m6A is near the 5S rRNA interaction site  [74, 75] (Figure 
1.2) [73]. These structure predictions, along with the fact that other rRNA modifications 
have been reported to be required for rRNA formation and function, suggests that the 
m6A modification may play an important role in translation [76, 77]. 
Function 
Understanding of the RBP’s that are regulated by or directly interact with m6A may lead 
us to better grasp the functional aspect of m6A. Currently, one of the biggest questions 
and challenges in the m6A field is correlating changes in m6A RNA with functional 
outputs. The RNA modification field is attempting to answer these questions, and many 
strides are being made. For example, the highly methylated long-noncoding RNA, XIST, 
along with m6A RBP YTHDC1 has been indicated to be involved in gene transcription 
silencing on the X chromosome [22]. In fact, loss of m6A on XIST impairs its function of 
silencing gene transcription on the X chromosome, but artificial binding of YTHDC1 to 
the m6A depleted XIST rescues its activity. Additionally, m6A has been implicated in the 
ultraviolet DNA damage response [34]. m6A methylated RNA briefly accumulates at 
DNA damage sites after UV irradiation, and in the absence of Mettl3, the DNA damage 





















Figure 1.2: Ribosomal rRNA with m6A modifications 
Predictive structure of small and large rRNA subunits together. Orange balls indicate 
m6A sites. White Helix is helix 44. Yellow ribbon is mRNA in the mRNA binding pocket. 





Interestingly, the m6A modification has also been found on many viral RNA 
genomes [36, 78-83]. It is well known that viruses evolve rapidly to evade environmental 
pressure, so it is assumed that any trait that is preserved must give an evolutionary 
advantage. Three different groups published reports that m6A in the viral RNA genome 
of HIV-1 increased infectivity of the virus through enhanced mRNA expression [79, 80, 
83]. This result could be attenuated by depleting YTHDF1,2, and 3 proteins which 
ultimately inhibited HIV-1 replication. This data suggests that YTHDF proteins may be 
potential targets of therapies of HIV-1 infected individuals. Inversely, however, it has 
been reported that m6A in a Flaviviridae family members, hepatitis C virus (HCV) and 
Zika virus, decreases infectivity [36, 81].  
m6A has also been reported to be important in embryonic stem cell differentiation 
[12, 13, 84]. A number of reports have suggested that m6A methylation is needed to 
drive embryonic stem cells towards differentiation. Loss of the methyltransferase 
complex leads to increased self-renewal and decreased differentiation of the stem cells 
[12, 84, 85] These reports have suggested that m6A specifically regulates expression of 
pluripotency genes including Nanog and Sox2 as well as signaling genes Notch1 and 
RhoCA [84, 85]. In contrast, an additional report suggested that m6A methylation drives 
stem cell self-renewal rather than differentiation [13]. This contrasting reported showed 
that developmental regulators including Sox1 and IgfBP3 were highly methylated and 
destabilized whereas pluripotency genes like Sox2 exhibited lower methylation and 
increased stability leading to self-renewal. One reviewer has suggested that the 
difference in these reports may be that m6A levels do not regulate the transition of stem 




This review suggests that stem cells exist in two states, a ground naïve state and a 
primed state ready to differentiate, and m6A simply aids in driving the continuation of 
the current state of the cell.  
Not only has m6A been revealed to regulate embryonic stem cells, but cancer 
stem cells as well, including breast cancer and glioblastoma stem cells [15, 86]. In both 
models, loss of m6A leads to enhanced cancer stem cell self-renewal and growth. 
Increased ALKBH5, leading to decreased m6A levels, in glioblastoma stem cells has 
also been directly implicated in increased tumorigenicity and self-renewal [87]. 
Exposure of breast cancer stem cells to a hypoxic environment leads to increased 
expression of the pluripotency factor NANOG through the reduction of m6A [15]. m6A 
levels were reduced in the breast cancer stem cells through an increase in the 
demethylase ALKBH5, as well sequestration of Mettl3 via increased levels of ZNF217 
[16, 88]. ZNF217 has previously been reported to be a poor prognosis marker in breast 
cancer glioma [89, 90]. In an additional model, decreased m6A in hepatocellular 
carcinoma (HCC) through the downregulation of Mettl14 also led to increased 
metastasis in HCC and poor patient prognosis [91]. Inversely, overexpression of 
Mettl14, leading to increased m6A, decreased metastasis in HCC. However, this same 
study showed that increased Mettl3 also increased the invasive ability of HCC. Another 
group also found that Mettl3 promotes translation in lung adenocarcinoma cells leading 
to increased growth and invasion of human lung cancer cells [38].  
As of yet, it has been difficult to reconcile these two differing results. One group 
shows that as part of the methyltransferase complex Mettl14 decreases, thereby 




shows that the other part of the methyltransferase complex, Mettl3, which increases 
m6A, promotes growth and invasion of cancer. Three possible explanations may 
account for this discrepancy. The first being that these two types of cancers are 
different, and therefore, the effect of m6A will not be the same on both. Another possible 
explanation is through the independent functions of Mettl3 and Mettl14. In the lung 
adenocarcinoma model, Mettl3 increased translation in the cancer cells [38]. However in 
the HCC model, Mettl14 regulated splicing of miR126 which has been identified as a 
metastasis suppressor [91]. So in the absence of Mettl14, mature miR126 was not 
available to suppress metastasis. In these cases, it may be possible that m6A levels are 
merely a side effect from the increased or decreased methyltransferase carrying out 
alternative functions. A third option may be that a decrease in Mettl14 in the HCC model 
may actually lead to free Mettl3 independently increasing translation. This possibility 
may actually account for both sides of the problem as the decreased miR126 and 
increased translation may both promote increased cell invasion. 
Hypoxia 
Understanding m6A’s role in hypoxia is vital because the hypoxic condition can 
occur during embryonic development and tumor growth where crowding and rapid cell 
division causes a shortage of blood and oxygen supply [92, 93]. Because changes in 
m6A have been implicated in the phenotypes of both embryonic and cancer stem cells, 
it is important to understand what effect the physiological presence of hypoxia will have 
on m6A, and ultimately on the cell’s phenotype. The amount of oxygen required for cells 
can vary depending on their location and function. For example, normal oxygen levels 




However, under hypoxic conditions, the cell becomes stressed and must overcome the 
low oxygen in order to survive. Alternatively, if the cell cannot overcome hypoxia, the 
cell may undergo apoptosis. Many tumors, however, not only survive in hypoxic 
conditions, they thrive [95-100].  
The hypoxic response is initiated by the stabilization of the hypoxia inducible 
factor-1α (HIF)-1α protein. HIF-1 is made up of two subunits. Under normal conditions 
HIF-1β is constitutively active whereas HIF-1α is degraded through binding of the von 
Hippel-Lindau (VHL) E3 ubiquitin ligase complex. The VHL- HIF-1α complex is 
mediated by hydroxylation of two proline residues via three members of a Fe(II)‐ and 2‐
oxoglutarate–dependent oxygenase family called prolyl hydroxylase (PHD) 1,2, and 3 
[101-107]. HIF-1α acts as a transcription factor that binds to genes with a hypoxia 
response element (HRE) in order to promote their transcription [108-111]. The hypoxic 
response is utilized in tumor growth because of its ability to turn on cellular pathways 
which are necessary for tumorigenesis. HIF-1α directly stimulates the transcription of 
VEGF, thus leading to increased tumor vascularization. HIF-1α also aids tumor cell 
migration through the upregulation of cell migration genes including C-X-C chemokine 
receptor type 4 (CXCR4) [96, 99, 112-115] mesenchymal epithelial transition factor (c-
MET), and insulin-like growth factor binding protein 1 (IGFBP1) [114, 116, 117].  
Recently, it has become clear that hypoxia not only has transcriptional regulation 
effects, but also affects post-transcriptional regulation. The stability of a subset of 
mRNA targets, including vascular endothelial growth factor (VEGF) and Glucose 
Transporter 1 (Glut1), increases during hypoxic stress [118]. For example, the stability 




signaling to VEGFR-2 receptors on endothelial cells ultimately increasing angiogenesis 
[119] in order to receive a greater blood supply thereby leading more oxygen to the area 
[120-123].  
The Mansfield lab has recently expanded upon these studies and identified 
numerous mRNAs stabilized in response to oxygen and glucose deprivation including 
VEGF, MYC, Hairy and Enhancer of Split 1 (Hes1), JUN, and Dual Specificity Protein 
Phosphatase 1 (DUSP1) [124]. As stated above, m6A plays a clear role in stability of 
mRNA, and my work has confirmed that m6A is required for the hypoxic stabilization of 
a subset of targets [11]. Because hypoxia is so important to tumor cell proliferation and 
migration, it is important to fully understand gene regulation during hypoxia, including 
regulation through m6A methylation. 
This dissertation project aims to advance the field of m6A modification by 
understanding its role in post-transcriptional regulation of mRNA during hypoxia. m6A 
has previously been reported to be involved in numerous post-transcriptional regulation 
processes including mRNA stability, splicing, and translational efficiency. In order to 
accomplish these regulation tasks, an RBP as described above must lead the 
methylated mRNA to its fate. Understanding the role of m6A methylation on the post-
transcriptional regulation processes in hypoxia will lead to a greater understanding of 
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Post-transcriptional regulation of mRNA during oxygen deprivation, or hypoxia, 
can affect the survivability of cells. Hypoxia has been shown to increase stability of a 
subset of ischemia-related mRNAs, including VEGF. RNA binding proteins and miRNAs 
have been identified as important for post-transcriptional regulation of individual 
mRNAs, but corresponding mechanisms that regulate global stability are not well 
understood. Recently, mRNA modification by N6-methyladenosine (m6A) has been 
shown to be involved in post-transcriptional regulation processes including mRNA 
stability and promotion of translation, but the role of m6A in the hypoxia response is 
unknown. In this study, we investigate the effect of hypoxia on RNA modifications 
including m6A. Our results show hypoxia increases m6A content of PolyA+ messenger 
RNA (mRNA), but not in total or ribosomal RNA in HEK293T cells. Using m6A mRNA 
immunoprecipitation, we identify specific hypoxia-modified mRNAs, including Glut1 and 
c-Myc, which show increased m6A levels under hypoxic conditions. Many of these 
mRNAs also exhibit increased stability, which was blocked by knockdown of m6A-
specific methyltransferases METTL3/14. However, the increase in mRNA stability did 
not correlate with a change in translational efficiency or the steady-state amount of their 
proteins. Knockdown of METTL3/14 did reveal that m6A is involved in recovery of 
translational efficiency after hypoxic stress. Therefore, our results suggest that an 
increase in m6A mRNA during hypoxic exposure leads to post-transcriptional 
stabilization of specific mRNAs and contributes to the recovery of translational efficiency 






Hypoxia is a metabolic condition that occurs when oxygen levels are deficient in 
cells or tissues. This stress can occur during embryonic development, where crowding 
and rapid cell division causes a shortage of blood and oxygen supply [92, 93]. Hypoxia 
can also be brought on by impaired blood flow due to heart attack or stroke [125, 126]. 
Other diseases can affect oxygen delivery including sickle cell disease and low blood 
pressure, which create hypoxic environments within the tissues. Regardless of the 
origins of the hypoxic stress, cells must alter their metabolism and gene expression in 
ways that will increase their chance of survival, or succumb to apoptosis.  
The physiological response to hypoxia is initiated by the stabilization of the HIF-
1α transcription factor targeting genes containing a HRE [108-111]. HIF-1α is also 
important for promoting cancer cell survival through interactions with Myc and Jun, and 
it is well documented that hypoxia drives tumor angiogenesis [95-99, 127, 128]. HIF-1α 
directly stimulates the transcription of VEGF. This hallmark of the hypoxic response 
leads to increased translation of VEGF promoting vascular growth in order to increase 
the blood supply to affected cells, thereby leading to increased oxygen [120-123]. The 
hypoxic response also aids tumor migration by upregulating the genes that are involved 
in the degradation of the extracellular matrix, as well as increasing the metastatic ability 
of the tumor and cellular proliferation through genes such as Dusp1 and Hes1 [96, 99, 
112, 113, 115, 129-131]. Because the hypoxic response is so important to cancer cell 
survival, it is critical to fully understand all mechanisms occurring during hypoxia 




Although the transcriptional response to hypoxia is well established, the post-
transcriptional response to oxygen deprivation is less understood. Post-transcriptional 
responses often regulate mRNA splicing and stability, and the stability of individual 
mRNAs, such as VEGF and Glut1 is increased with hypoxic exposure [118]. We have 
recently expanded upon these studies and identified numerous mRNAs stabilized in 
response to oxygen and glucose deprivation including VEGF, MYC, Hes1, JUN, and 
DUSP1 [124]. Specific sequences in VEGF mRNA 3’ UTR and ORF have also been 
discovered to contribute to the stabilization of VEGF in response to hypoxia, but this 
analysis has not been extended to other mRNAs [121, 122, 132-134]. It has also been 
well documented that severe oxygen deprivation leads to inhibition of global cap-
dependent translation, but post-transcriptional regulation of a subset of mRNAs allows 
for continued translation through a number of proposed mechanisms [135-140]. The 
hypoxic response has also recently been implicated in global changes in alternative 
splicing [141, 142]. Thus, it is clear that post-transcriptional regulation of mRNAs has a 
role in the hypoxic response, but the mechanisms involving this regulation have not all 
been identified.  
Recently, m6A mRNA modification has been shown to be important for the 
stability and translational efficiency of mRNA [6-10]. m6A methylation is a post-
transcriptional modification of mRNA occurring in the nucleus [17, 18, 20]. The m6A 
methyltransferase complex consists of Methyltransferase like -3 and -14 (METTL3 and 
METTL14), as well as WTAP [17-19]. METTL3 contains a SAM binding domain, and 
utilizes SAM as a substrate to methylate target mRNAs that contain a DRACH m6A 




METTL14 lacks catalytic activity but participates in mRNA binding/targeting [28-30]. 
m6A methylation of RNA is reversible and can be removed by ALKBH5 or FTO [39-46]. 
Methylated mRNA is transported out of the nucleus and bound by RNA binding proteins, 
including most members of the YTH family [9, 56, 57]. While much is known about the 
mechanisms of m6A writing and erasing, the broader consequences of RNA 
methylation are still being investigated. m6A methylation has been shown to mark 
mRNA for degradation, mediated by YTHDF2 transport to P bodies where degradation 
of mRNA occurs [9, 23, 40, 61]. Additionally, YTHDF1 has recently been reported to 
stimulate translational efficiency of m6A methylated mRNA thereby increasing 
translational output [10].  
It is known that through post-transcriptional regulation, the fate of mRNAs can 
change based on the changing conditions of the cell [143]. Post-transcriptional 
modifications like m6A may alter the fate of RNA by potentially altering secondary 
structure, the ability of RNA binding proteins to bind, or the position of splicing events 
[58, 60, 68, 144, 145]. Changes at the RNA level can occur rapidly, and are necessary 
to adapt to rapidly changing microenvironments. RNA modifications can also direct 
permanent changes within the cell, as is the case of m6A modifications that limit the 
pluripotency of embryonic stem cells [12-14].  Defects in these post-transcriptional 
modifications could cause problems in rapid cell response mechanisms, embryonic 
development, or even promote tumor growth.  
m6A mRNA has received much attention in recent years, allowing the factors 
involved in m6A mRNA methylation to be identified. However, the importance of 




pluripotency of stem cells in embryonic development [12-14], as well as the induction of 
a cancer stem cell phenotype in breast cancer cells has been described [15, 16].  
However, the m6A modification may function in other responses, including adaptation to 
changing cellular environments. Therefore, it is quite possible that the m6A modification 
may be involved in post-transcriptional hypoxic response mechanisms. Understanding 
the shifting landscape of m6A mRNA in hypoxic cells will shed light on not only how 
post-transcriptional regulation is altered when oxygen is lacking, but also the extent of 
m6A post-transcriptional utilization within a cell under other dynamic conditions.  
 
Results 
Effect of Hypoxia on cellular RNA modification levels 
Changes in the m6A modification of mRNA have been shown to regulate stem 
cell pluripotency during embryonic development as well as breast cancer stem cell 
phenotypes. We investigated whether a cellular stress that is present in both of these 
models, hypoxia, has any effect on RNA modification levels, including m6A. To do this, 
HEK293T cells were incubated for 24 hours under normoxic or hypoxic (1% O2) 
conditions in the presence of 1 g/L glucose to mimic the nutrient deprivation 
encountered during ischemic events. Total RNA was isolated, dotted onto a nylon 
membrane, and m6A levels were detected with an m6A-specific antibody.  As shown in 
Figure 2.1A, exposure of HEK293T cells to hypoxic conditions resulted in a dramatic 
decrease in the total RNA m6A content as detected by the m6A antibody. To further 




enriched by oligo-dT selection followed by rRNA depletion (Figure 2.2), and after 
fragmentation, liquid chromatography and tandem mass spectrometry (LC-MS) was 
used to quantify various RNA modifications in the mRNA enriched samples. 
Surprisingly, in contrast with a recent report measuring m6A in total RNA and specific 
mRNAs in breast cancer cells [15], global PolyA+ RNA showed a significant increase in 
m6A content in HEK293T cells exposed to hypoxia (Figure 2.1E). This result was 
confirmed by m6A dot blot (Figure 2.1B). Other mRNA modifications, including 5-
methylcytidine, showed no significant differences in hypoxia (Figure 2.3). This data 
shows that the mRNA modification, m6A, has a dynamic response to hypoxia. 
As rRNA makes up 80-85% of the cellular RNA mass, we postulated that 
diminished M6A content in total RNA observed here and by others [15] derived chiefly 
from changes in rRNA methylation. This was demonstrated directly by isolating 40 and 
60S ribosomal subunits via differential centrifugation through sucrose gradients. rRNA 
was isolated from the fractions, subjected to qPCR to verify the composition of the 
fractions (Figure 2.4), and then dot blotted for M6A. A clear decrease in m6A content in 
both 18S and 28S rRNA in HEK293T cells exposed to hypoxia was shown (Figure 
2.1C). We used LC-MS to confirm these changes in total, and rRNA, and contrary to our 
dot blot results, m6A levels were unchanged in hypoxia (Figure 2.1 D, F). However, 5-
methylcytidine and N1-methylguanosine were significantly decreased in total RNA 
(Figure 2.5). Similarly to total RNA, 5-methylcytidine exhibited a statistically significant 
decrease in content in 18S RNA, and N1-methylguanosine exhibited a decreasing trend 
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Figure 2.1: m6A levels in total, Poly A+, and rRNA  
(A) RNA isolated from HEK-293T cells grown in Normoxic (N) or Hypoxic (H) conditions 
for 24 hours. Top Panel.  Immunoblot with m6A antibody of 1 µg of total RNA. Bottom 
Panel. Methylene Blue Stain of total RNA showing equal loading of RNA. (Image is 
representative of 5 biological replicates). (B) m6A Immunoblot of 100 ng of PolyA RNA 
from HEK-293T cells grown in Normoxic or Hypoxic conditions. (Image is representative 
of 3 biological replicates). (C) m6A Immunoblot of 1 µg 18S and 28S ribosomal rRNA 
isolated via differential centrifugation through sucrose gradients. (Image is 
representative of 3 biological replicates). (D) LC-MS/MS of Total RNA from HEK-293T 
cells. Values represent the amount of m6A divided by total Adenosine (N of 2). (E) LC-
MS/MS of mRNA from HEK-293T cells. Values represent the amount of m6A divided by 
total Adenosine (N of 5). (F) LC-MS/MS of 18 and 28S rRNA from HEK-293T cells. 
Values represent the amount of m6A divided by total Adenosine (N of 3).  



















































Figure 2.2: Depletion of rRNA in PolyA+ RNA samples 
qRT-PCR verification of rRNA depletion in PolyA+ RNA. Both 18 and 28S rRNA from 
cells cultured in Normoxic or 24 hours Hypoxic conditions were depleted over 70-fold 




























































































































































































































































































Figure 2.3 UPLC-MS/MS of Poly A+ RNA from HEK-293T cells. Values represent the 
amount of the modification divided by total parent levels (N of 2). *P ≤ 0.05 by Paired 












































































Figure 2.4: Confirmation of ribosomal sub-units 
40 and 60S ribosomal subunits from HEK-293T cells grown in normoxic or hypoxic 
conditions for 24 hours were separated by differential centrifugation followed by sucrose 
gradient fractionation. qRT-PCR of individual fractions reveals purity of respective 
rRNAs in each fraction. Fractions containing 40S and 60S peaks are marked.  Fractions 







in content in the isolated 28S rRNA, but no changes were detected in total RNA (Figure 
2.5 and 2.6). These results suggest that not only mRNA modifications, but also specific 
rRNA modifications are dynamically altered after 24 hours of hypoxic conditions. 
However, for this study we chose to focus on the effects of hypoxia on the mRNA m6A 
content given its reported effects on mRNA regulation. 
Identification of differentially methylated mRNAs 
Given that we saw dynamic changes in the m6A content of mRNA, we next 
wanted to determine if m6A methylation of specific mRNA targets involved in the 
adaptive response was affected when cells were exposed to hypoxia. Using m6A RNA 
immunoprecipitation (MeRIP), target mRNAs related to hypoxia and tumorigenesis 
including Glut1, Jun, Myc, DUSP1, and Hes1 were investigated. HEK293T cells were 
exposed to 24 hours of normoxia or hypoxia and PolyA mRNA isolated via oligo dt 
selection and ribosomal RNA depletion. m6A containing mRNAs were then 
immunoprecipitated using an m6A-specific antibody. Following cDNA synthesis, the 
relative enrichment of the indicated mRNAs were determined using qPCR. The targets 
were quantified relative to input RNA and the negative IP. Interestingly, many of the 
hypoxia-associated and tumorigenic mRNAs from hypoxic cells, including Glut1 and 
Jun, increased more than 2-fold in the m6A captured fraction, as compared to the 
normoxic conditions (Figure 2.7). This signifies an increase in the m6A content of these 
mRNAs in response to hypoxic exposure. It is likely that these and other mRNAs 
contribute to the enhanced m6A content of PolyA+ RNA (Figure 2.2E).  Importantly, 
mRNAs such as Human antigen R (HuR) and METTL3 showed no change in m6A 










































































































































































































































































































Figure 2.5. UPLC-MS/MS of Total RNA from HEK-293T cells. Values represent the 
amount of the modification divided by total parent levels (N of 2). *P ≤ 0.05 by Paired 





























































































































































































































































































































Figure 2.6. UPLC-MS/MS of Ribosomal RNA from HEK-293T cells. Values represent 
the amount of the modification divided by total parent levels (N of 3). *P ≤ 0.05 by 



























































Figure 2.7: m6A increases in individual targets after hypoxia 
MeRIP of 100 ng of mRNA from HEK-293T cells grown in Normoxic or Hypoxic 
conditions for 24 hours quantified by qRT-PCR. Fold enrichments calculated from 
immunoprecipitated mRNA levels normalized to input and bead-only negative control IP 
and expressed as a ratio of hypoxia/normoxia.  *P ≤ 0.05 by Paired Student’s t-test 








Loss of m6A Prevents Hypoxic mRNA stabilization 
 To address if m6A methylation plays a role in stabilization of these particular 
mRNAs as part of their post-transcriptional response to hypoxia, METTL3 and 
METTL14 of the m6A methyltransferase complex were knocked down via siRNA and 
the half-lives of our target mRNAs were determined. Knockdown of METTL3 and 
METTL14 was confirmed via western blot analysis (Figure 2.8).  Depletion of m6A 
content in individual mRNAs was confirmed by MeRIP followed by qPCR (Figure 2.9A).  
After depletion of METTL3 and METTL14 for 48 hours, HEK293T cells were transferred 
to either normoxic or hypoxic conditions for 24 hours to simulate ischemia. During the 
last hour of treatment, newly transcribed RNA was metabolically labeled using 4-
thiouridine (4sU). RNA was harvested, the 4sU labeled RNA was biotinylated, and 
streptavidin beads were used to separate the new labeled RNA from unlabeled RNA. 
RNA half-lives were determined from the ratio of the labeled to unlabeled RNA 
normalized to total RNA. As shown in Figure 2.9B, many of the mRNAs that had 
increased m6A methylation in hypoxic conditions (Glut1, Jun, Dusp1 and HES1) also 
showed a significant increase in mRNA half-life. Interestingly, knockdown of METTL3/14 
had no effect on the normoxic half-life of any of the mRNAs, but loss of the 
methyltransferases did significantly inhibit their hypoxic stabilization. eEFA1, which 
exhibited no change in m6A level (data not shown) also showed no loss of stabilization 
after METTL3/14 depletion. Therefore, mRNAs that were stabilized under hypoxic 
conditions lost that stabilization after an engineered decrease in m6A levels. This 
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Figure 2.8: Mettl3 and 14 KD confirmation and Protein output is not affected by 
loss of m6A. HEK-293T cells harvested after 72 hours transfection with METTLl3/14 
(M3/14) or negative control (Neg) siRNA and 24 hours of normoxic or hypoxic 



































































































































































































Figure 2.9: Transfection with METTL3 and METTL14 siRNAs decrease m6A levels. 
(A). HEK-293Ts transfected with METTL3 and 14 siRNAs (KD) or negative control 
siRNA (Neg) for 72 hours and 24 hours of normoxic or hypoxic exposure followed by 
MeRIP and qRT-PCR quantitation shows decreased M6A levels in mRNA targets after 
Mettl3/14 knockdown. (N of 1) (B)Total RNA from HEK-293T cells was harvested after 
72 hours transfection with METTL3/14 (M3/14) or negative control (Neg) siRNA and 24 
hours of normoxic or hypoxic conditions and half-life determined via 4SU.  # denotes P 
≤ 0.05 by Paired Student’s t-test between negative siRNA samples in normoxic and 
hypoxic conditions while *denotes P ≤ 0.05 by Paired Student’s t-test between negative 








hypoxic post-trasncriptional regulation. 
The effect of m6A on mRNA translation and protein levels 
 Having determined that changes in m6A content affected mRNA stabilization, we 
next examined how methylation might affect the translation of these messages. 
HEK293T cells were again depleted of METTL3/14 for 48 hours, and transferred to 
either normoxic or hypoxic conditions for 24 hours followed by 15 minutes of 
cyclohexamide treatment and fractionation of cellular extracts on sucrose gradients. 
Polysome profiles (Figure 2.10 A-D) were analyzed by qRT-PCR for specific mRNA 
targets. Sedimentation position as shown by polysome profiling allowed us to determine 
how efficiently each message was being translated. During sucrose gradient resolution, 
mRNAs partition based on the number of ribosomes bound, which is a direct measure 
of their translational efficiency. For example, mRNA such as Beta-2-Microglobulin (β2M) 
which is found to peak in fraction 8 in normoxic conditions, is considered to be 
moderately translated, while an mRNA that is primarily located in fractions 10 and 11, 
such as Glut1, is bound heavily by polysomes indicating highly efficient translation 
(Figure 2.11). In general, hypoxic exposure caused a decrease in translational efficiency 
(as indicated by a left-ward shift in the gradient) of assayed mRNAs. The extent of the 
decrease depended on the mRNA being investigated.  Surprisingly, depletion of m6A 
via METTL3/14 knockdown had no effect on the polysome loading of any of the tested 
mRNAs, suggesting that m6A does not play a role in their translational efficiency (Figure 
2.11).  
 To determine if increased m6A during hypoxia was involved in the recovery after 
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Figure 2.10: Polysome Profile traces.  
(A-D) Traces of Polysome Profiles from Figure 2.11. (A), Normoxia, (B), Normoxia 
M3/14 siRNA, (C), Hypoxia, (D) Hypoxia M3/14 siRNA. (E-F) Traces of Polysome 




























































































































































Figure 2.11: Translation rates and are not affected by loss of m6A. HEK-293T cells 
harvested after 72 hours transfection with METTL3/14 (M3/14) or negative control (Neg) 
siRNA and 24 hours of normoxic or hypoxic conditions. Polysome Profiling extracts 
separated by differential centrifugation followed by sucrose gradients.  qRT-PCR 
analysis of fractions show percentage of individual mRNA. Error bars represent SEM of 







re-oxygenation of HEK293T cells with and without METTL3/14 knockdown. Polysome 
profiles were obtained similarly to the previous experiments with the exception that cells 
were exposed to room level oxygen for 0.5, 1, or 4 hours prior to cyclohexamide 
treatment and fractionation of cellular extracts on sucrose gradients. Profiles (Figure 
2.12) were again analyzed by qRT-PCR for our specific mRNA targets. After four hours 
of re-oxygenation, recovery of translational efficiency of Glut1, Jun, Dusp1, Hes1, and 
Myc was diminished by METTL3/14 knockdown compared to negative control siRNA 
transfected cells (Figure 2.13, Figure 2.14). These results suggest that m6A may be 
aiding the cellular response to recovery after stress.  
All of the mRNAs shift from heavier to lighter fractions in cells exposed to hypoxic 
conditions; however some mRNAs shifted farther into lighter fractions than others. For 
example, β2M and 18S shift completely out of polysomes into the sub-ribosomal 
fractions 2-3. However, Glut1 and Jun shifted only moderately from heavy fractions, with 
the majority of the mRNA being found in fractions 5 through 7. This initially suggested 
that Glut1 and Jun were still being moderately translated under hypoxia as has been 
previously reported [146]. However, it was also possible that mRNAs such as Glut1 and 
Jun had actually been released from the translating ribosomes, but were still in a large 
ribonucleoprotein complexes which might also increase their sedimentation in the 
gradient. To test whether the mRNAs were still bound by intact ribosomes and hence 
translating, extracts were treated with EDTA prior to sucrose sedimentation (Figure 2.10 
E-F).  EDTA chelates the magnesium necessary for large and small ribosomal subunit 
association, releasing all mRNAs to presumably sediment slower in their non-translating 
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Figure 2.12: Reoxygenation Polysome Profile traces.  
(A-F) Traces of Polysome Profiles from Figure 2.13. (A), 30min reoxygenation negative 
siRNA, (B), 30min reoxygenation m3/14 siRNA, (C), 1hr reoxygenation negative siRNA, 
(D), 1hr reoxygenation m3/14 siRNA, (E), 4hr reoxygenation negative siRNA, (F),4hr 
reoxygenation m3/14 siRNA. (Traces represent 1 of 3 experiments). 
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Figure 2.13: Mettl3/14 KD decreased the ability of messages to recover from 
hypoxia after 4 hours re-oxygenation. HEK-293T cells harvested after 72 hours 
transfection with Mettl3/14 (M3/14) or negative control (Neg) siRNA and 24 hours of 
hypoxia and either 0.5, 1 or 4 hours of room level re-oxygenation recovery. Polysome 
Profiling extracts separated by differential centrifugation followed by sucrose gradients. 
qRT-PCR analysis show percentage of individual mRNA in each fractions. Error bars 
represent SEM of 3 in the 1 and 4 hour time points and SEM of 2 in the 30 minute time 
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Figure 2.14. Mettl3/14 Knockdown decreased the ability of messages to recover 
from hypoxic stress after 4 hours re-oxygenation. HEK-293T cells harvested after 
72 hours transfection with Mettl3/14 (M3/14 KD) or negative control (Neg) siRNA and 24 
hours of hypoxic conditions and either 30 minutes, 1 hour or 4 hours of room level re-
oxygenation recovery. Polysome Profiling of extracts separated by differential 
centrifugation followed by sucrose gradients. qRT-PCR analysis followed by binning into 
estimated non-polysome (1,2,3), light polysome (4,5,6), moderate polysome (7,8,9), and 
heavy polysome (10,11,12) bound fractions show percentage of individual mRNA in 
each bin. Error bars represent SEM of 3 experiments in the no re-oxygenation, 1 and 4 
hour re-oxygenation experiments and SEM of 2 experiments in the 30 minute re-
oxygenation experiment. N of 1 Myc hypoxia experiment is shown. *P ≤ 0.05 by Paired 






to light fractions just as observed with hypoxia with or without EDTA treatment (compare 
Figure 2.15 to Figure 2.11). However, Glut1 and Jun only shifted modestly from the 
heavier fractions to intermediate fractions, despite being released from ribosomes. The 
sedimentation of these mRNAs in intermediate fractions may indicate association with 
previously uncharacterized ribonucleoprotein complexes which are unaffected by EDTA 
metal chelation. 
We attempted to correlate the mRNA translational efficiency to the steady-state 
level of their protein products. If m6A increases the stability of these mRNAs under 
hypoxic conditions, and knocking down m6A decreases their stability but maintains their 
translation, one might expect to see a decrease in their protein after m6A knockdown. 
However, western blotting for these proteins under normoxia and hypoxia after 
METTL3/14 knockdown showed no changes in protein levels of Glut1, Myc, and Dusp1 
(Figure 2.8). There was also no observed changes in protein levels after re-oxygenation 
even though polysome analysis suggested that METTL3/14 knockdown decreased 
translational efficiency after 4 hours of recovery (Figure 2.16). This suggests that other 
factors likely are involved in determining the steady-state levels of proteins derived from 
these mRNAs. Interestingly, METTL3/14 knockdown also had no significant effect on 




















































































































Figure 2.15: EDTA-resistant RNP particles are observed for several hypoxia-
modified mRNAs.  
Polysome Profiling following addition of 25mM EDTA added to the lysis buffer. qRT-
PCR analysis of the fractions shows percentage of the specific mRNA in each fraction. 
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Figure 2.16: No observed changes in protein levels after re-oxygenation. 
Western blots of 50 µg of protein lysates of normoxic negative control siRNA (NNeg), 
normoxic METTL3/14 Knockdown (NKD), hypoxic negative control (HNeg), hypoxic 
METTL3/14 Knockdown (HKD), and 1,2,4, or 8 hours re-oxygenation after hypoxia. 



















































Figure 2.17: HEK-293T cell proliferation after Mettl3/14 KD. Mettl3/14 Knockdown 
(m3/14 KD) had no significant effect on cell proliferation in HEK-293T cells grown in 
Normoxic (Normox) or 24 hour Hypoxic (Hypox) conditions when compared to negative 







 Our findings suggest that m6A mRNA methylation of certain mRNAs is induced 
by hypoxia. Furthermore, increased m6A prolongs the half-life of specific mRNA targets. 
Although, the increased stability of these messages did not correlate with translational 
efficiency or changes in protein levels during hypoxia, we found that loss of m6A 
through METTL3/14 knockdown decreased the cells ability to recover translational 
efficiency after re-oxygenation following hypoxic stress. We also observed that under 
hypoxic conditions some mRNAs may be associated with other ribonucleoprotein 
complexes instead of actively translating polysomes.   
 
Discussion 
m6A has received renewed attention over the past few years as a dynamic mRNA 
modification with many potential cellular functions. Although the factors involved in m6A 
mRNA methylation have been identified, the importance of mRNA methylation remains 
unclear. We now suggest a role for dynamic changes in mRNA m6A content in regulating 
mRNA stability in response to oxygen deprivation. In contrast to the total and rRNA, we 
saw a significant increase in the m6A content of mRNA levels in hypoxic cells, suggesting 
that the m6A modification may be important for regulating mRNAs in hypoxia. Our LC-
MS/MS results also indicate the presence of other dynamic RNA modifications in PolyA+, 
total and Ribosomal RNA after 24 hours of hypoxia, but we have yet to identify what the 




Immunoprecipitation of m6A followed by qRT-PCR allowed us to determine the 
m6A methylation status of individual mRNAs. We observed an increase of m6A in 
specific mRNA targets after hypoxic exposure. However, this method cannot determine 
how hypoxia affects m6A methylation at specific sites. In follow up studies, we will seek 
to determine if hypoxia introduces m6A in new sites and if so, determine how specificity 
is regulated. It is possible that a hypoxic switch in methylation sites, for example 
switching methylation from the 5’ end to the 3’ end of the mRNA, could also alter the 
regulation of the mRNA without affecting the overall m6A level.  
Others have previously reported that stability of individual mRNAs was increased 
by hypoxia [122, 124, 147-149]. It is also known that m6A can affect the stability of 
mRNAs [9, 13]. We now show that an increase in m6A methylation is correlated with 
increased stabilization of a number of mRNAs under hypoxic conditions. We confirmed 
the stabilization of Glut1 and Myc mRNA under hypoxia [124, 150] but also identified 
several novel targets including Dusp1, Hes1, and Jun. Interestingly, these findings 
contradict suggestions that increased methylation leads to increased degradation of 
mRNAs through YTHDF2 association [15]. The two data sets are not directly 
comparable however, as stability of those messages had not been reported under 
hypoxic conditions. There are a number of possible reasons for this discrepancy.  
Hypoxia may switch the location of the methylation allowing for different functions of the 
YTH family proteins, or equally possible, an entirely different RNA binding protein may 
be interacting with these hypoxically methylated mRNA. We will attempt to probe these 




Even though m6A increased the stability of certain mRNAs under hypoxic 
conditions, there was no noticeable effect on translational efficiency or protein level. 
Polysome profiling detected no substantial changes in translation between samples 
containing or lacking METTL3/14. Remarkably, even though mRNA stability was 
increased, there was no detectable change in protein levels of Glut1, Myc, and Dusp1 
as determined by western blotting. Interestingly, even though METTL3/14 knockdown 
did not affect translation, hypoxia itself caused a shift from heavier polysomes to a 
lighter complex. This shift to lighter fractions was more robust in some mRNAs than 
others. It was previously thought that this lack of a complete shift out of polysomes 
ultimately indicated the maintenance of translation. Indeed, it has previously been 
reported that numerous mRNAs including Hif-1α and Glut1 continue to associate with 
polysomes during hypoxic conditions [146, 151]. However, our data now suggest that 
these messages may be being maintained in mRNPs that do not contain 80S 
ribosomes, based on their resistance to EDTA-mediated disruption of ribosome 
association. None of the previous reports tested for this possibility.  
Knockdown of METTL3/14 did decrease the ability of cells to recover 
translational efficiency after 4 hours of re-oxygenation following hypoxia. Detection of 
protein levels by western blotting after re-oxygenation again showed little difference with 
or without METTL3/14 KD, but polysome profiling showed decreases in translational 
efficiency after 4 hours of re-oxygenation in specific messages including Glut1, Hes1, 
Dusp1, and Myc suggesting that m6A’s role in hypoxia may be related to recovery after 
the hypoxic stress rather than adaption to the stress. It is possible that the difference 




possible that we could not detect these subtle changes in protein levels accurately with 
western blotting. Utilizing a more physiologically relevant cell model or investigating this 
phenomenon in vivo might reveal situations in which m6A exerts a more dramatic effect 
in the adaptation to and recovery from hypoxic exposure. 
Overall, this study demonstrates that hypoxic exposure can indeed induce 
changes in multiple RNA modifications.  In particular, the m6A modification of mRNA is 
necessary for increased stability under hypoxic conditions.  Future studies will explore 
these m6A changes with base-specific precision, as well as the RNA binding proteins that 
interact with the m6A modification under hypoxia. It is our goal to gain a better 
understanding of mRNA dynamics in response to hypoxia with the hope of developing 
new therapeutics targeting cardiovascular disease, cancer and other diseases that 
involve periods of reduced oxygen.  
 
Materials and Methods 
Cell Lines 
HEK293T (HEK293T/17; CRL-11268) cells were obtained directly from ATCC 
(Manassas, VA) and maintained in high glucose (4g/L) DMEM (Corning/Mediatech, 
Manassas, VA) supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 
2mM Glutamine (Corning/Mediatech), and 1X Pen/Strep (Corning/Mediatech) and 
passaged when approximately 85-90% confluent.  Cells were tested for mycoplasma 
upon receipt. For experiments, cells were plated on 10cm dishes (CytoOne, USA 




18-24 hours.  The next day, the media was removed and replaced with media 
containing 1 g/L glucose.  Hypoxic treatments were carried out in a Ruskin In Vivo 400 
Hypoxia Hood (The Baker Company, Sanford, ME) maintained at 37°C, 5% CO2, 70% 
humidity and 1% oxygen. All other chemical reagents were obtained from Sigma-Aldrich 
(St. Louis, MO) unless otherwise specified.   
 
RNA extraction 
Trizol (Life Technologies, Carlsbad, CA) was used for all RNA extractions according to 
the manufacturer's protocol. RNA was further purified and treated with RNase-Free 
DNase I (Life Technologies) using PureLink RNA Mini Kit (Life Technologies). For RNA 
extraction from ribonucleoprotein immunoprecipitations (RNP-IP) and sucrose 
gradients, GlycoBlue (Life Technologies) was added as a carrier during the precipitation 
step. RNA quality and quantity was determined via NanoDrop 1000 (ThermoFisher 
Scientific, Waltham, MA). 
 
PolyA+ RNA purification 
PolyA+ RNA was first purified from total RNA through oligo DT selection using a 
Poly(A)Purist-MAG magnetic mRNA Purification Kit (Life Technologies) followed by 
ribosomal RNA depletion using RiboMinus Eukaryote Kit (Life Technologies) according 
to the manufacturer’s protocols.  
 




PolyA+ RNA was hydrolyzed enzymatically by first denaturing the RNA at 95⁰C followed 
by immediate placement on ice. PolyA+ RNA was incubated with S1 nuclease buffer 
and 1 unit of S1 nuclease (Life Technologies) per 300 ng of RNA for 30 minutes at 
37⁰C. Alkaline phosphatase buffer, 1 unit of Alkaline Phosphatase per 300 ng of RNA 
(Life Technologies), and .00025 units of venom phosphodiesterase I (Sigma-Aldrich) 
was added to incubate for 30 minutes at 37⁰C. Fragmented RNA was purified through 
two round of chloroform extraction. LC-MS/MS quantification of m6A and adenine was 
performed by Craft Technologies (Wilson, NC). Separations and identification by LC-
MS/MS were performed using a Thermo Finnigan Linear Ion Trap Quadrapole (LTQ) 
mass spectrometer utilizing an electrospray ionization interface in selected reaction 
monitoring mode connected to Agilent 1100 autosampler and Agilent 1100 HPLC pump 
system (Agilent). Detection was performed using an electrospray ionization source 
operated in positive ion mode. 
 
LC-MS/MS of PolyA+, Total, and Ribosomal RNA for nucleoside modification 
analysis 
Purified RNA was digested to individual nucleosides and modified nucleosides were 
quantified as previously described [36]. Briefly, digestion was performed with nuclease 
P1 (Sigma, 2U) in buffer containing 25 mM NaCl and 2.5 mM ZnCl2 for 2h at 37⁰C, 
followed by incubation with Antarctic Phosphatase (NEB, 5U) for an additional 2h at 
37⁰C. Nucleosides were then separated and quantified at the Duke Molecular 
Physiology Institute using UPLC-MS/MS as previously described [152], except acetic 





Ribosomal Subunit Separation 
Cells grown in normoxic or hypoxic conditions were harvested in “Buffer A” (35mM Tris 
pH 7.5, 70mM KCL, 9mM MgCl, 0.1 mM EDTA, 250mM sucrose, 0.5% Sodium 
Deoxycholate, 1% Triton X 100, 1x Protease Inhibitors, 1mM DTT, and RNase out). Cell 
lysate was centrifuged for 15 minutes at 15,000 x g in a Beckman TLA 100 rotor. The 
supernatant was removed to a new tube and centrifuged in the same rotor at 150,000 x 
g for 90 minutes. Ribosome pellets were resuspended in “Buffer B” (10mM Tris pH 7.5, 
500mM KCL, 10mM MgCl2 1x Protease Inhibitors 1mM DTT and RNase out) and 
layered on a 12mL 15-30% sucrose gradient in buffer B. The gradient was centrifuged 
at 86,000 x g for 14 hours in a Beckman SW-41 Ti swinging bucket rotor. 1 mL fractions 
were collected from the top of the gradient and the positions of the 40S and 60S 
ribosomal subunits were found by measuring each fraction at an absorbance at 254 nm. 
RNA was isolated from each sample via Trizol.  
 
m6A mRNA Immunoprecipitation (MeRIP) 
m6A Ribonucleoprotein Immunoprecipitation reactions were performed by first isolating 
PolyA+ RNA from normoxic and hypoxic cells. Protein G Dynabeads (Thermo Fisher 
Scientific, Baltics UAB) were washed 3X in 1 mL of IPP buffer (10mM Tris-HCL pH7.4, 
150mM NaCl, 0.1% NP-40). 25 µl of beads required per IP. Anti-N6-methyladenosine 
mouse monoclonal antibody (EMD Millipore, Temecula, CA, MABE1006) was added to 
the beads (5 µg/IP) and brought up to 1mL with IPP buffer. As a negative control, beads 




Beads were washed 5X with IPP buffer and 100ng of PolyA+ RNA was added to the 
beads along with 1mM DTT and RNase out. The mixture was brought up to 500 µl with 
IPP buffer. Bead mixture was tumbled at 4⁰C for 4 hours. Beads were washed 2X in IPP 
buffer, placed into a fresh tube, and washed 3X more in IPP buffer. m6A RNA was 
eluted off the beads by tumbling 2X with 125 µl of 25mg/mL N6-Methyladenosine-5’-
monophosphate sodium salt (CHEM-IMPEX INT’L INC., Wood Dale, IL). Supernatant 
was added to Trizol-LS followed by RNA isolation as per manufacture’s protocol. Final 
RNA sample was brought up in 10 µl of water. 
 
PCR for MeRIP 
Reverse transcription was performed on 10 µl m6A PolyA+ RNA from the MeRIP with 
the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA).  After diluting 
cDNA two-fold, quantitative real-time PCR was performed using a Roche Lightcycler 96 
with Fast Start Essential DNA Green (Roche Diagnostics Corporation, Indianapolis, IN) 
and primers from Integrated DNA Technologies, Inc. (Coralville, Iowa). Primer efficiency 
was verified to be over 95% for all primer sets used.  Quantification of mRNA from the 
MeRIP was carried out via ΔΔCT analysis against non-immunoprecipitated input RNA 
and RNA pulled down from non-antibody bound beads. All real-time PCR primer sets 
were designed so the products would span at least one intron (>1kb when possible), 
and amplification of a single product was confirmed by agarose gel visualization and/or 
melting curve analysis. 
 




Either a negative siRNA (Silencer; Life Technologies, Carlsbad, CA) or METTL3 and 
METTL14 siRNAs (Qiagen, Germantown, MD) transfected together using Lipofectamine 
RNAi Max 54 µl/plate as per manufacturer’s protocol (Life Technologies) using 180 pM 
siRNA/10 cm dish. Cells were incubated for 48-72 hours post-transfection with the last 
24 hours in either normoxic or hypoxic conditions.  
 
4SU 
mRNA half-life determinations using 4SU were performed as per established protocol 
[153]. Cells were treated with 200 µM 4SU (Sigma-Aldrich) for 1 hour. RNA isolated via 
Trizol was biotinylated by labeling 50 µg RNA in a reaction mixture with 50 µl 10x 
Tris/EDTA buffer (TE), 100 µl 1mg/ml Biotin-HPDP (EZ-Link Biotin HPDP, Thermo 
Scientific, Waltham, MA) in Dimethylformamide (DMF), and RNase free H2O brought to 
400 µl. Mixture was incubated in the dark with rotation for 1.5 hours. Biotinylated RNA 
was extracted using an equal volume of Chloroform/Isoamyl alcohol (24:1) 2x in phase 
lock gel heavy tubes (5 Prime, Gaithersburg, MD) followed by RNA precipitation with 
isopropanol. RNA was heated to 65⁰C for ten minutes and placed immediately on ice. 
RNA was added to Dynabeads MyOne Streptavidin C1 (Thermo Fisher Scientific) that 
had been thoroughly washed and resuspended in 2X streptavidin binding buffer (2X TE, 
2M NaCl). The RNA bead mixture was incubated with rotation for 30 minutes. Beads 
were washed 5X with 65⁰C Wash Buffer (1XTE, 1M NaCl, 0.1% Tween20) and the 
supernatant was kept containing the non-labeled RNA. Three rounds of 100 mM 
Dithiothreitol (DTT) elution followed by 1 round of TE eluted labeled RNA from the 






mRNA levels were determined by real-time quantitative PCR using 1 µl of RNA from 
both labeled and unlabeled 4SU samples. Decay rates were calculated by the natural 
log of 1 minus the RNA input normalized ratio of labeled over unlabeled RNA. All half-
lives were normalized to GAPDH half-life which was defined as 8 hours based on 
previous publications and our unpublished data [154]. 
 
Polysome Profiling 
Cells were treated with 200 µM cyclohexamide for 15 minutes prior to harvest. Cells 
were harvested in PLB buffer (100mM KCl, 5mM MgCl2, 10mM Hepes, 0.5% NP40, 200 
µM cyclohexamide, 1mM DTT, 1x Protease Inhibitors, RNase out) and incubated on ice 
for 30 minutes. Lysates were pre-cleared by centrifugation for 8 minutes at 5000 x g. 
Supernatant was layered on a 10-45% sucrose gradient in Polysome Profile Buffer (300 
mM KCl, 50mM Hepes, 10mM MgCl2, 200 µM cyclohexamide). The gradient was 
centrifuged at 38,000 x g for 1 hour 45 minutes in a Beckman SW-41 Ti swinging bucket 
rotor. Twelve 1 mL fractions were collected from the top of the gradient and the 
polysomes were measured from lightest to heaviest at an absorbance at 254 nm. RNA 
was isolated from each sample via Trizol.  
 
Profiling PCR 
Reverse transcription was performed on 1 µl of RNA from each fraction in a 20 µl 




Percentages of mRNA per fraction was carried out via ΔCT analysis using a baseline 




Whole cell lysates were prepared in whole cell extract buffer (WCEB: 50 mM Tris pH 
7.4, 150 mM NaCl, 5 mM EDTA, 0.1% SDS, and complete protease inhibitor (Promega, 
Madison, WI)). Equal amounts of protein (30-50 μg) were electrophoresed on a mini-
PROTEAN any KD acrylamide gel (Bio-Rad Laboratories, Hercules, CA) and 
transferred to Hybond ECL nitrocellulose (GE Healthcare, Chicago, IL).  Transfer was 
verified via Ponceau S staining then blot was blocked with 5% nonfat dry milk 
(LabScientific, Highlands, NJ) in Tris buffered saline with 0.1% Tween 20 (TBST) for 
one hour at room temperature, followed by primary antibody in blocking buffer overnight 
at 4°C.  After washing extensively with TBST, blots were incubated for 1-2 hours at 
room temperature with appropriate HRP-linked secondary antibody (GE Healthcare), 
washed again with TBST, developed using Pierce ECL Western Blotting Substrate 
(ThermoFisher Scientific, Waltham, MA), and exposed to film for detection.   
 
Statistical Analysis 
All experiments were performed on at least three separate occasions to generate 
biological replicates unless otherwise indicated. qPCR was performed at least twice on 
each cDNA for technical verification of data.  Half-lives were calculated for each 




error of the mean. Statistical significance was calculated by a two-tailed, paired 
Student's t-test comparing experimental to control conditions. A P-value below 0.05 was 
defined as statistically significant. 
 
Primer List 
Gene Forward (5'-3') Reverse (5'-3') 
18S rRNA CTGAGAAACGGCTACCACATC GCCTCGAAAGAGTCCTGTATTG 
28S rRNA GGGTGGTAAACTCCATCTAAGG GCCCTCTTGAACTCTCTCTTC 
5.8S 
rRNA CTCGTGCGTCGATGAAGAA TCGAAGTGTCGATGATCAATGT 
5S rRNA CGTCTGATCTCGGAAGCTAAG CCTACAGCACCCGGTATTC 
β2M AGATGTCTCGCTCCGTGGCCTTA TGTCGGATGGATGAAACCCAGACA 
Dusp1 CAACCACAAGGCAGACATCA CAGTGGACAAACACCCTTCC 
eEF1A1 CGGTCTCAGAACTGTTTGTTTC AAACCAAAGTGGTCCACAAA 
GapDH AAGGTCGGAGTCAACGGATTTGGT AGCCTTGACGGTGCCATGGAATTT 
Glut1 TATCGTCAACACGGCCTTCACTGT CACAAAGCCAAAGATGGCCACGAT 
Hes1 GAAGGCGGACATTCTGGAAAT GTCACCTCGTTCATGCACTC 
HuR CCTGTTCAGCAGCATTGGTGAAGT TTCAGCGTGTTGATCGCTCTCTCT 
Jun TTCTATGACGATGCCCTCAAC TCAGGGTCATGCTCTGTTTC 
METTL3 AGCCTTCTGAACCAACAGTCC CCGACCTCGAGAGCGAAAT 
Myc TCCTCGGATTCTCTGCTCTCCT AGAAGGTGATCCAGACTCTGACCT 










siRNA Target Sequence 
siMETTL3 CTGCAAGTATGTTCACTATGA 
siMETTL14 AAGGATGAGTTAATAGCTAAA 














c-Jun MA5-15119 Thermo Fisher 1/100  
c-Myc NBP1-19671 
Novus 
Biologicals 1/1000  
GAPDH (G-9) sc-365062 
Santa Cruz 
Biotechnology 1/100  
Glut1  PA5-16793 
 
Thermo Fisher 1/250  
METTL14 HPA038002 
Sigma Life 
Science 1/1000  
METTL3/MT-A70  A301-567A 
Bethyl 
Laboratories 1/5000  
MKP-1 (c-19)    (DUSP1) sc-370 
Santa Cruz 
Biotechnology 1/100  
N6-methyladenosine (m6a) MABE1006 
 














The mRNA modification, N6-methyladenosine (m6A), has recently been shown to 
be involved in many post-transcriptional regulation processes including mRNA stability 
and translational efficiency. While understanding these mechanisms are useful, it is also 
imperative to correlate these processes with phenotypic outputs. Here we report that 
m6A levels are decreased in genetically defined immortalized and oncogenically 
transformed human mammary epithelial cells (HMECs) as compared with their primary 
cell predecessor. Interestingly, after 24 hours of hypoxic exposure, m6A levels in the 
immortal and transformed cells were increased back to primary cell levels. It was also 
found that the m6A methyltransferase, Mettl3, is decreased and the demethylase, 
Alkbh5, is increased in the immortalized and transformed cell lines, possibly explaining 
the decrease in m6A in those cells. However, changes in Mettl3 and Alkbh5 do not 
explain the increase in m6A in hypoxia. m6A levels appear increased in hypoxic 
conditions not because of changes in methyltransferase or demethylase levels, but 
rather because of a build-up of stabilized m6A mRNA. At first glance, it would appear 
that transformation of the HMECs reduces m6A levels possibly to obtain a more 
progressive phenotype.  In actuality, increasing m6A levels through overexpression of 
Mettl3 and Mettl14 increased proliferation, migration, and invasion of the transformed 
cells. Remarkably, overexpression of Mettl3 and Mettl14 had little effect on the 
immortalized cells, suggesting that the m6A modification may regulate migration and 






It is estimated that there will be over 250,000 new cases of breast cancer in the 
United States in 2017, and over 40,000 Americans are expected to lose their lives to 
breast cancer in 2017 [155]. The 5 year survival rate for patients diagnosed with 
localized breast cancer is nearly 99%. Unfortunately, patients with stage IV metastatic 
breast cancer have less than a 30% survivability rate [156, 157]. Gene expression 
profiles of breast cancer have been extensively studied, but more progress needs to be 
made for early detection and proper personalized treatment for the disease. Because of 
this, it is important to study post-transcriptional and translational pathways that regulate 
de novo gene expression in breast cancer cells with the eventual goal of identifying 
better therapeutic targets for suppressing growth and metastasis of tumor cells.   
Recently, the mRNA modification, m6A has been shown to be involved in many 
post-transcriptional regulation processes. It has been discovered that m6A levels are 
directly correlated to metastasis and poor patient prognosis in hepatocellular carcinoma 
(HCC). In fact, a decrease in m6A content led to increased metastasis of HCCs [91]. 
Interestingly, loss of m6A through an increase in ALKBH5, an m6A demethylase, also 
led to enhanced breast and glioblastoma cancer stem cell self-renewal and growth [15, 
86, 87]. Inversely, an increase in the m6A methyltransferase, Mettl3, led to increased 
invasion of lung adenocarcinoma cells [38]. While it is clear that the function of m6A is 
diverse throughout many cell types, it is also important to understand the role that the 
m6A modification plays in all tumors.  
Because tumors often quickly outgrow their blood supply, they have to adapt to 




HIF mediated angiogenesis [158]. Not only does HIF increase vascularization of the 
tumor to increase blood and oxygen supply, but it is also known to promote metastasis 
of the cells [159-161]. Interestingly, ALKBH5, an m6A demethylase, is also regulated by 
HIF [162]. Recently, it was reported that a HIF-regulated decrease in m6A through an 
increase in ALKBH5 and or ZNF217 maintains pluripotency of breast cancer stem cells 
in a number of established breast cancer cell lines [15, 88]. Interestingly, we recently 
reported that hypoxia led to an increase in m6A mRNA levels in HEK-293T cells 
ultimately leading to increased stability and recovery of translational efficiency after 
reoxygenation [11]. Because hypoxia both regulates m6A levels and promotes 
metastasis in breast cancer cells, it is important to understand if m6A might have a role 
in hypoxia mediated breast cancer metastasis. 
The m6A modification is the most abundant modification in mRNA [4]. This 
modification has been shown to be important for the stability and translational efficiency 
of mRNA [6-11], and is involved in the pluripotency of stem cells in embryonic 
development [12-14].  Methyltransferase like -3 and -14, as well as Wilms’ tumor 
associating protein (WTAP) form the m6A methyltransferase complex which methylates 
nascent pre-mRNA within the nucleus [17-21]. The enzymatically active component of 
the methyltransferase, Mettl3, contains an S-adenosyl methionine (SAM) binding 
domain, and utilizes SAM as a substrate to methylate target mRNAs that contain a 
DRACH m6A consensus sequence, often found in 3` UTR’s and around both start and 
stop codons [17, 24-27]. METTL14 lacks catalytic activity but participates in mRNA 
binding/targeting [28-30]. WTAP is responsible for the localization of the Mettl3/14 




bringing the methyltransferase to the pre-mRNA. m6A methylation of mRNA is 
reversible and can be reportedly removed by alkylation repair homolog 5 (ALKBH5) and 
fat mass and obesity related protein (FTO) [39-48]. However, recent data suggests that 
FTO prefers the modification N6,2′-O-dimethyladenosine (m6Am) as a substrate rather 
than m6A [53].  
Methylated mRNA is transported out of the nucleus and bound by the YTH family 
RNA binding proteins, including YTHDF1, YTHDF2, and YTHDC1 [9, 56, 57]. The 
broader consequences of RNA methylation through the actions of these and other RNA 
binding proteins are still being investigated. However, YTHDF2 has been shown 
facilitate degradation of methylated mRNAs by transporting them to P bodies [9, 23, 40, 
61]. Alternatively, binding of YTHDF1 increases translational efficiency of m6A 
methylated mRNA [10]. Lastly, YTHDC1 recruits splicing factors to regulate splicing of 
m6A methylated mRNA [64]. The interactions between these RNA binding proteins is 
not fully understood, and competition between them may yield different results for the 
mRNA and ultimately for the protein output. 
m6A methylation has recently been correlated with a number of phenotypic 
changes in cancers including in breast cancer stem cells. Many of these phenotypic 
changes are the result of changing protein expression of either the m6A 
methyltransferases, demethylases or RNA binding proteins. These studies show that 
m6A has a functional significance in cancer, but further investigation is required in order 
to understand the intricacies of the m6A mechanisms when compared with non-
cancerous cells. In this study, we hypothesize that m6A methylation plays a role in the 





Because diagnosing breast cancer early while it is still localized provides a much 
better outcome and survival rate, it is important to fully understand breast cancer 
progression. However, because cancers have many diverse mutations and alterations 
to gene regulation, it is difficult to pinpoint exactly which changes introduce aggressive 
phenotypic behavior. For this reason, we chose to use a genetically defined breast 
cancer progression model for these studies. In this model, three cell types are utilized, 
primary Human Mammary Epithelial cells (HMECs), HMECs immortalized through the 
stable expression of hTERT, p53DD, cyclin D1, CDK4R24C, and C-MYCT58A, and a further 
oncogenically transformed line expressing with H-RASG12V in addition to the above 
alterations (Figure 3.1) [163]. hTERT is the catalytic subunit of telomerase which helps 
the cells avoid senescence, resulting in a potentially unlimited lifespan. The p53DD 
construct expresses a dominant negative form of the tumor suppressor p53 lacking 
DNA binding and transactivation domain that inhibits tetramerization and prevents it 
from regulating the cell cycle, apoptosis, and differentiation.  This effectively nullifies 
cellular checkpoints in response to DNA damage, etc. The CDK4R24C mutant is resistant 
to inhibition and along with CyclinD1 overexpression leads to hyperphosphorylation of 
Rb further disrupting cell cycle checkpoint function.  The T58A mutation of the proto-
oncogene CMYC confers resistance to degradation by preventing threonine 
phosphorylation.  This promotes cellular proliferation as well as altered metabolism.  
Finally, the H-RASG12V oncogene supports growth factor-independent cell proliferation 




We first investigated whether m6A levels were altered in our breast cancer progression 
model, and what effect hypoxia had on m6A in the HMEC cell lines. HMEC primary, 
immortalized, and oncogenically transformed cells were incubated for 24 hours under 
normoxic or hypoxic (1% O2) conditions.  PolyA+ mRNA was isolated by oligo-dT 
selection followed by ribosomal RNA (rRNA) depletion, and after fragmentation, liquid 
chromatography and tandem mass spectrometry (LC-MS/MS) were used to quantify 
various RNA modifications in the mRNA enriched samples. Interestingly, when 
compared to the primary HMECs, m6A levels were decreased in the immortalized and 
transformed cell lines under normal growing conditions. However, in hypoxic conditions 
the m6A levels in the immortal and transformed lines were increased to levels 
comparable to the primary cells, which surprisingly showed no change (Figure 3.2). 
Many other mRNA modifications, including 5-methylcytidine and 2-O-methyladenosine 
were unchanged in the immortalized and transformed cells, further highlighting the need 
to understand why m6A levels are specifically changed (Figure 3.3). 
Protein Levels of m6A methyltransferases and demethylases 
 In order to investigate the dynamic response of m6A to cellular 
transformation as well as hypoxia, RNA and protein levels of the m6A-associated 
enzymes and effectors were measured through qRT-PCR and Western Blotting 
following SDS-PAGE. . Interestingly, many of the proteins involved with m6A, including 
methyltransferases, demethylases, and RNA binding proteins exhibited notable 
changes upon immortalization and oncogenic transformation of the HMEC cells. 
Hypoxia, however, had very little effect on protein levels. Fascinatingly, the mRNA 























Figure 3.1: HMEC cancer progression cell lines. Outline of the cellular transformation 
in the genetically defined human mammary epithelial cancer cells. In this model, three 
cell types are utilized, primary Human Mammary Epithelial cells (HMECs), HMECs 
immortalized through the stable expression of hTERT, p53DD, cyclin D1, CDK4R24C, and 
C-MYCT58A, and a further oncogenically transformed line expressing with H-RASG12V in 














































Figure 3.2: m6A decreases in immortalized and oncogenically transformed cells 
in normoxic but not hypoxic conditions.  
LC-MS/MS determination of m6A levels in mRNA isolated from primary, immortalized, 
and oncogenically transformed (transformed) HMEC cells grown in Normoxic (Normox) 
or Hypoxic (Hypox) conditions for 24 hours. Values represent the amount of m6A 
divided by total Adenosine (N of 3). *P ≤ 0.05 by Paired Student’s t-test. Error bars 























































































































































































































Figure 3.3: UPLC-MS/MS of Poly A+ RNA from HMEC cells cultured in Normoxic or 
Hypoxic conditions for 24 hours. Values represent the amount of the modification 
divided by total parent levels (N of 3). *P ≤ 0.05 by Paired Student’s t-test. Error bars 

















































































































































Figure 3.4: qRT-PCR of m6A players qRT-PCR of m6A methyltransferases, 
demethylases, and m6A RNA binding proteins of HMEC cells cultured in Normoxic or 
Hypoxic conditions for 24 hours. (N of 3). Data shows relative ratio of RNAs compared 





Protein levels of the enzymatically active subunit of the methyltransferase, Mettl3, were 
decreased in immortalized and transformed cells, but Mettl14 expression was increased 
(Figure 3.5). In addition, ZNF217, which is known to sequester Mettl3 and inhibit its 
methyltransferase activity [16], is also increased in the immortalized and transformed 
cells. Also in agreement with the decreased m6A levels, the demethylases ALKBH5 and 
FTO were both increased in the immortalized and transformed cells. This data 
suggested that the loss of m6A observed in the transformed cells is due to a loss of the 
methyltransferase, Mettl3, and the increase of the demethylases, ALKBH5 and FTO.  
The m6A-recognizing RNA binding proteins YTHDF1, YTHDF2 and YTHDC1 
were also altered in the immortalized and transformed cells lines.  YTHDF1 levels were 
increased, but YTHDF2 levels were decreased in the immortalized and transformed 
cells. The blots for YTHDC1 interestingly contained a shift from a lower molecular 
weight (the correct expected molecular weight) to a much higher molecular weight (the 
observed molecular weight given in the details of the antibody). The switch in protein 
levels from YTHDF2 to YTHDF1 suggests that the primary outcome of the m6A function 
is no longer degradation of the mRNA, but rather increased translational efficiency. 
Unfortunately, the observed protein levels of the methyltransferase, demethylases or 
RNA binding proteins were unable to explain the increase in m6A levels in hypoxia 
suggesting that the m6A increase in hypoxia must be due to some other process. 
Differential methylation in specific mRNAs 
Protein levels of m6A methyltransferases and demethylases could not explain why m6A 
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Figure 3.5: Protein levels of m6A methyltransferases, demethylases and RNA 
binding proteins.  
Western blots of 50 µg of protein lysates of normoxic (N) or hypoxic (H) primary (pri), 
immortalized (immo), and oncogenically transformed (trans) HMEC cells. 






explanations could explain the increase of m6A in hypoxic cells. We have recently 
reported that the m6A modification stabilizes mRNA in hypoxic conditions in HEK293T 
cells [11]. Therefore, it is possible that the increase of m6A is simply due to a build-up of 
stabilized methylated mRNA. Secondly, it is possible that methylation rates have 
increased in newly transcribed RNA in hypoxic conditions. In order to test this second 
possibility m6A RNA immunoprecipitation (MeRIP) as described previously [11] was 
used to initially identify specific mRNA targets that increased m6A levels after 24 hours 
of hypoxic conditions. Not surprisingly, many of the same targets identified in our 
previous report using HEK-293T cells, including Glut1, Jun, VHL, and Dusp1 also 
increased m6A levels in the oncogenically transformed HMEC line (Figure 3.6 blue 
bars). MeRIP of the immortalized cells showed a similar trend as seen in the 
transformed cells while no significant differences in m6A levels in these same targets 
were observed in the Primary cells (Figure 3.7). This data demonstrates an increase in 
the m6A content of these mRNAs from transformed HMECs in response to hypoxic 
exposure.  
  Additionally, the increase of m6A in specific mRNA targets in hypoxic conditions 
were compared to m6A in newly transcribed RNAs. In order to measure methylation 
rates of newly transcribed RNA in hypoxia, a uridine analog, 4-thiouridine (4sU), was 
added to the culture media one hour until harvest to be incorporated into all newly 
transcribed RNA. This newly transcribed RNA was then biotinylated and separated from 
old (unlabeled) mRNA using streptavidin beads. After elution of the newly transcribed 
RNA from the streptavidin beads, MeRIP was then used to pull down m6A methylated 

















































Figure 3.6: m6A methylation rates are decreased in hypoxic transformed HMEC 
cells.  
(Blue Bars) MeRIP of 100 ng of mRNA from oncogenically transformed cells or (Red 
Bars) 100 ng of newly transcribed RNA isolated via 4-thiouracil labelling, biotinylation 
and streptavidin pull downs. Cells were grown in Normoxic or Hypoxic conditions for 24 
hours and RNA was quantified by qRT-PCR. Fold enrichments calculated from 
immunoprecipitated mRNA levels normalized to input RNA and expressed as a ratio of 































































































Figure 3.7: m6A IP in Primary and Immortalized HMECs MeRIP of 100 ng of mRNA 
from HMEC primary (A) or immortalized (B) cells grown in Normoxic or Hypoxic 
conditions for 24 hours quantified by qRT-PCR. Fold enrichments calculated from 
immunoprecipitated mRNA levels normalized to input mRNA and expressed as a ratio 
of hypoxia/normoxia.  *P ≤ 0.05 by Paired Student’s t-test. Error bars represent SEM of 





and Dusp1 mRNA had a decreasing trend of m6A methylation (Figure 3.6 red bars), 
suggesting that methylation rates of these newly transcribed RNAs were not increasing. 
This data then also suggests that the increase in m6A in hypoxic conditions was not due 
to a change in the methylation rates of newly transcribed mRNA, but rather a buildup of 
stabilized mRNAs. 
HIF controls hypoxic m6A levels in specific targets 
 To further investigate how m6A is increased under hypoxia, we wanted to 
determine if Hypoxia Inducible Factor (HIF) was involved. HIF-1α and HIF-2α were 
knocked down via siRNA in oncogenically transformed cells which were then exposed 
to hypoxia. Knockdown of HIF-1α and HIF-2α was confirmed via western blot analysis 
(Figure 3.8).  m6A content in individual mRNAs were measured once again by MeRIP 
followed by qPCR. Knockdown of HIF-1α and HIF-2α prevented the hypoxic increase in 
m6A levels in many of our specific targets including Glut1, VHL, and Dusp1 (Figure 3.9). 
This suggests that the increase in m6A in hypoxia is at least partially due to the hypoxic 
induction of HIF. 
Phenotypic effects of m6A on breast cells 
 The goal of this project was not only to understand the differences in m6A levels 
between the stages of a genetically defined breast cancer model, but also to understand 
how those changes affect the cells phenotypically. Because the immortalized and 
oncogenically transformed cell lines contained decreased m6A levels, it was initially 
hypothesized that increasing m6A content in these cells might lead to a primary-like cell 
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Figure 3.8 Protein levels of Mettl3/14 after overexpression, Alkbh5 after 
Knockdown, and HIF-1 and 2α after knockdown. 
Western blots of 50 µg of protein lysates of control (Cntl), Overexpression (OE) or 
knockdown (KD) of immortalized (immo), and oncogenically transformed (trans) cells. 
HIF KD blots compare normoxia (N) with or without knockdown (NKD and hypoxia (H) 






















































Figure 3.9: Hypoxic increases in m6A are HIF dependent. 
MeRIP of 100 ng of mRNA from oncogenically transformed cells. Cells were cultured 
with or without HIF-1α and HIF-2α 72 hour knockdown and either Normoxic or Hypoxic 
conditions for 24 hours. RNA was quantified by qRT-PCR. Fold enrichments calculated 
from immunoprecipitated mRNA levels normalized to input RNA and expressed as a 
ratio of hypoxia/normoxia. For statistical analysis, ratios of hypoxia/normoxia were 
compared between control and HIF knockdown samples.  *P ≤ 0.05 by Paired Student’s 
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Figure 3.10: Mettl3 and 14 Overexpression leads to increased proliferation of 
oncogenically transformed HMECs 
(A) Mettl3/14 overexpression (OE) significantly increased cell proliferation in 
oncogenically transformed HMECs cells when compared to negative plasmid 
transfection (cntl). (N of 3) (B) Mettl3/14 overexpression did not significantly increase 
cell proliferation in immortalized HMEC cells, however, there is an increasing trend of 






lines was significantly increased after Mettl3 and Mettl14 overexpression, however, the 
immortalized cells were not affected. Additionally, wound healing scratch assays 
showed that Mettl3 and 14 overexpression aided the transformed cells in wound 
healing, however very little differences were seen in immortalized cells when compared 
to controls (Figure 3.11 A-E and 3.12 A-E). In addition, a trend showing increased 
wound healing via knockdown of the demethylase ALKBH5 in transformed cells, but not 
in immortalized cells, suggests that this effect is due to increased m6A levels rather 
than increased Mettl3/14 levels (Figure 3.13A-E, 3.14A-E).  Confirmation of Mettl3/14 
overexpression and Alkbh5 knockdown is shown in Figure 3.8.  Furthermore, upon 
Mettl3 and 14 overexpression, transformed cells, but not immortalized cells (data not 
shown) showed increased invasion through matrigel (Figure 3.15 A-E). These 
phenotypic assays suggest that increased m6A in the transformed cells did not revert 
these cells to a more primary-like cell state but instead increased their metastatic 
potential. Remarkably, in terms of wound healing, increased m6A actually mimicked the 
response to hypoxic conditions (Figure 3.16 A-E). Hypoxia led to increased m6A in the 
transformed cells (Figure 3.2), and increased wound healing (Figure 3.16A-E), but had 
little effect on wound healing in the immortalized cells (Figure 3.17A-E). Overall, this 
suggests that m6A may not play a role in cellular transformation, but rather aids and 












B.     Cntrl 0 hr   C.      Cntrl 24 hr 
  
 






































Figure 3.11: Mettl3/14 Overexpression increases wound healing in oncogenically 
transformed HMECs 
(A) Mettl3/14 overexpression (OE) significantly increased wound healing after 24 hours 
in oncogenically transformed HMECs cells when compared to negative plasmid 
transfection (control). (N of 3) 
(B-E) Images of scratch assays of negative plasmid transfection (Control) and Mettl3/14 
Overexpression (OE) at 0 and 24 hour time points. (Images representative of 3 
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Figure 3.12: Mettl3/14 Overexpression does not increase wound healing in 
immortalized HMECs 
(A) Mettl3/14 overexpression (OE) had little effect on wound healing after 24 hours in 
immortalized HMECs cells when compared to negative plasmid transfection (control). (N 
of 3) 
(B-E) Images of scratch assays of negative plasmid transfection (Control) and Mettl3/14 
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Figure 3.13: Demethylase ALKBH5 knockdown increases wound healing in 
Oncogenically Transformed HMECs. 
(A) Alkbh5 Knockdown (KD) increased wound healing after 24 hours in oncogenically 
transformed HMECs cells when compared to negative plasmid transfection (control). (N 
of 3) 
(B-E) Images of scratch assays of negative plasmid transfection (Control) and Alkbh5 
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Figure 3.14: Demethylase ALKBH5 knockdown does not increase wound healing 
in immortalized HMECs 
(A) Alkbh5 knockdown (KD) had little effect on wound healing after 24 hours in 
immortalized HMECs cells when compared to negative plasmid transfection (control). (N 
of 3) 
(B-E) Images of scratch assays of negative plasmid transfection (Control) and Alkbh5 
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Figure 3.15: Mettl3/14 Overexpression increases invasion in oncogenically 
transformed HMECs 
(A) Mettl3/14 overexpression (OE) significantly increased invasion of oncogenically 
transformed HMECs cells when compared to negative plasmid transfection (control). (N 
of 4). Average invading cells shows number of cells that crossed the matrigel. 
(B) Images of membrane from matrigel invasion assays of negative plasmid transfection 
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Figure 3.16: Hypoxia increases wound healing in oncogenically transformed 
HMECs 
(A) Hypoxia (Hypox) significantly increased wound healing after 24 hours in 
oncogenically transformed HMECs cells when compared to normoxia (Normox). (N of 3) 
(B-E) Images of scratch assays of normoxic and hypoxic conditions at 0 and 24 hour 
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Figure 3.17: Hypoxia does not increases wound healing in immortalized HMECs 
(A) Hypoxia (Hypox) had little effect on wound healing after 24 hours in immortalized 
HMECs cells when compared to Normoxia (Normox). (N of 3) 
(B-E) Images of scratch assays of normoxic and hypoxic conditions at 0 and 24 hour 







 These findings indicate that m6A methylation levels can be altered in human 
breast cancer cells when compared with their normal primary cell countertype. 
Specifically, in this model, m6A decreases upon immortalization, and further decreases 
upon oncogenic transformation of human mammary epithelial cells. Additionally, 
consistent with our previous findings, hypoxia increases mRNA m6A levels in 
transformed cell types [11]. Ultimately, these increases in m6A in hypoxia are HIF 
regulated, and are not due to increased protein levels of the methyltransferase or 
methylation rates. Interestingly, increasing m6A methylation by overexpressing the 
methyltransferases and/or hypoxic exposure in the transformed cells led to further 
developed cancer-like phenotypes indicating that differing stages of cells may utilize 
m6A in different ways in order to increase their own chances for survival and growth. 
Discussion 
Although gene expression in breast cancer has been extensively studied, the role 
of RNA modifications in breast cancer is not well known. Studies involving these RNA 
modifications, including the m6A modification, may lead to a better understanding of 
gene regulation in breast cancers and potentially other cancers as well. This report 
utilizes a genetically defined progressive breast cancer model which is advantageous in 
studying gene regulation because any phenotypic changes may be mapped back to a 
specific genetic alteration.  
In this study, LC-MS/MS results indicate that the m6A modification decreases 




data seemed to suggest that the loss of the m6A modification may lead to a more 
oncogenic phenotype. However, hypoxia, a cellular stress condition involved in 
increasing tumorigenic phenotypes, drives the m6A modification back to near normal 
primary cell levels. Previous reports have shown total RNA m6A levels in breast cancer 
stem cells decrease in hypoxia conditions through HIF mediated induction of the 
demethylase ALKBH5 and Mettl3 sequestration by ZNF217 [15, 88]. These reports 
indicated that hypoxia induces the breast cancer stem cell phenotype through the 
decrease in m6A. The results seen here differ from these previous reports possibly due 
to differences in model systems. For example, these previous reports show that m6A 
levels in specific mRNA, including Nanog, is decreased in hypoxia. However, Nanog is 
not highly expressed in our cell lines so no differences in m6A were observed (data not 
shown).  In addition, these previous results also used total RNA rather than mRNA to 
measure differences in global m6A levels.  
To understand why m6A levels are increased in hypoxic conditions in our model 
system in the immortalized and oncogenically transformed cells, protein expression of 
the methyltransferase, demethylases, and m6A RNA binding proteins were measured. 
Interestingly, the enzymatically active subunit of the methyltransferase complex, Mettl3, 
is decreased in the immortalized and transformed cells, and ZNF217 which sequesters 
Mettl3 is increased. Additionally, the two known m6A demethylases, ALKBH5 and FTO, 
increase in the immortalized and transformed cells. Therefore, it can be concluded that 
the decrease in m6A methylation in the immortalized and transformed cells is due to a 
loss in methylation potential and an increase in demethylation potential. In addition, 




immortalized and transformed cells. YTHDF2, an m6A RNA binding protein which leads 
to degradation of the methylated RNA [9, 40], decreased in the immortalized and 
transformed cells. In contrast, YTHDF1, another m6A specific RNA binding protein 
involved in methylated mRNA translational efficiency increases in the immortalized and 
transformed cells [10]. These contrasting changes in RNA binding proteins suggest that 
the remaining methylated RNA have increased translational efficiency through 
increased YTHDF1 levels and an increase in stability due to a decrease in YTHDF2 
levels. The RNA binding protein YTHDC1 interestingly appears expressed at a higher 
molecular weight in the immortalized and transformed cells. This may possibly be due to 
dimerization of YTHDC1, however this has not been confirmed. It would also not explain 
why YTHDC1 would dimerize in certain cell types but not in others. It was also observed 
that hypoxia does not lead to changes in any of the aforementioned proteins suggesting 
that the increase of m6A in this stress condition cannot be explained by through protein 
expression.   
Because the increase of m6A in hypoxia cannot be explained by protein levels of 
methyltransferases and demethylases, alternative explanations including methylation 
rates of newly transcribed RNAs were investigated. We previously reported that 
increased m6A methylation in hypoxia leads to stabilization of mRNAs [11]. Therefore it 
is possible that the increase in m6A methylation is due to stabilization and accumulation 
of methylated mRNAs. However, in order to test if methylation rates increased in 
hypoxic conditions, newly transcribed RNAs were pulse-labeled, isolated and 
immunoprecipitated using an m6A antibody. These experiments showed that 




trending towards a decrease in specific targets where m6A levels were initially 
increased. Therefore, it seems likely that the increase in m6A levels is simply due to the 
accumulation of stabilized mRNA. However, there are a few other potential but unlikely 
possibilities that we have yet to investigate. It is possible that methylation is occurring to 
some degree within the cytoplasm in order to methylate mature mRNA, or that 
decreased demethylation is occurring on cytoplasmic mRNA. A recent study however, 
has shown that m6A methylation is not dynamic within the cytoplasmic, which would 
suggest that neither methylation nor demethylation levels are altered [21]. 
Because the hypoxic response through HIF is crucial for survival and 
tumorigenesis of cancer cells under hypoxic conditions, the effect of HIF on m6A levels 
in hypoxia was measured. Previous reports once again contradict these results showing 
that in breast cancer stem cells, hypoxic activation of HIF led to decreased RNA 
methylation through HIF mediated induction of the demethylase ALKBH5 and Mettl3 
suppressor ZNF217 [15, 88]. However, because in our model system there is an 
increase in m6A in hypoxia rather than a decrease, HIF may be regulating these 
changes in m6A as well. Indeed, knockdown of HIF decreased m6A levels in many of 
our specific targets including Glut1, Dusp1, and VHL suggesting that HIF is responsible 
for the increase in m6A in these targets. The conflicting data with the previous report 
may be explained through a difference in model system, and highlights the importance 
of understanding the m6A modification in all breast cancer systems.   
Understanding mechanisms behind m6A methylation is important in breast 
cancer, as it may lead to a better understanding of the cancer itself. However, it is also 




stated previously, immortalization and oncogenic transformation of HMEC cells led to a 
decrease in m6A methylation. Initially, it seemed possible that an increase of m6A in 
these transformed cells would drive cells towards a more primary phenotype. However, 
m6A was increased after 24 hours of hypoxia, a condition known to promote 
tumorigenesis. Ultimately, when Mettl3 and Mettl14 were overexpressed thereby 
increasing m6A levels, the oncogenically transformed cells exhibited increased 
proliferation, wound healing, and invasion. Increased wound healing was also seen in 
these same cells under hypoxia. Through these results, it appears likely that an 
increase in m6A either through methyltransferase overexpression or a HIF mediated 
increase in hypoxia leads to a more cancerous phenotype. Interestingly, the 
immortalized cells did not show the same effect as the oncogenically transformed, 
suggesting that the increased m6A was working in tandem with active expression of the 
Ras pathway in order to alter these phenotypes. While we cannot completely rule out 
the possibility that the overexpression of Mettl3 and Mettl14 itself had an effect on these 
phenotypes, it seems likely that the phenotypic changes are m6A dependent as 
knockdown of the demethylase ALKBH5 had similar effects to overexpression of Mettl3 
and Mettl14. 
In conclusion, this study demonstrates that m6A methylation is important for the 
phenotypic progression of breast cancer. Hypoxia plays a role in this progression 
through increases m6A levels in breast cancer through HIF activation. This hypoxic 
response can be mimicked in normal cells by overexpressing the methyltransferase 
subunits Mettl3 and Mettl14.  




Materials and Methods 
Cell Lines 
HMEC Primary cell lines cells were obtained directly from Lonza (Walkersville, MD) and 
maintained in Mammary Epithelial Basal Medium (MEBM) (Lonza) and supplemented 
with Mammary Epithelial Cell Growth Medium (MEGM) BulletKit (Lonza) along with 
2mM Glutamine (Corning/Mediatech), and 1X Pen/Strep (Corning/Mediatech) and 
passaged when approximately 85-90% confluent.  Cells were tested for mycoplasma 
upon receipt. For experiments, cells were plated on 10cm dishes (CytoOne, USA 
Scientific, Orlando, FL) allowed to attach/recover for 18-24 hours.  The next day, the 
media was removed and replaced with fresh media.  Hypoxic treatments were carried 
out in a Ruskin In Vivo 400 Hypoxia Hood (The Baker Company, Sanford, ME) 
maintained at 37°C, 5% CO2, 70% humidity and 1% oxygen. All other chemical 
reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise specified.   
 
RNA extraction 
Trizol (Life Technologies, Carlsbad, CA) was used for all RNA extractions according to 
the manufacturer's protocol. RNA was further purified and treated with RNase-Free 
DNase I (Life Technologies) using PureLink RNA Mini Kit (Life Technologies). For RNA 
extraction from ribonucleoprotein immunoprecipitations (RNP-IP) and sucrose 
gradients, GlycoBlue (Life Technologies) was added as a carrier during the precipitation 
step. RNA quality and quantity was determined via NanoDrop 1000 (ThermoFisher 





PolyA+ RNA purification 
PolyA+ RNA was first purified from total RNA through oligo DT selection using a 
Poly(A)Purist-MAG magnetic mRNA Purification Kit (Life Technologies) followed by 
ribosomal RNA depletion using RiboMinus Eukaryote Kit (Life Technologies) according 
to the manufacturer’s protocols.  
 
LC-MS/MS of PolyA+ RNA 
Purified PolyA+ RNA was digested to individual nucleosides and modified nucleosides 
were quantified as previously described [36]. Briefly, digestion was performed with 
nuclease P1 (Sigma, 2U) in buffer containing 25 mM NaCl and 2.5 mM ZnCl2 for 2h at 
37⁰C, followed by incubation with Antarctic Phosphatase (NEB, 5U) for an additional 2h 
at 37⁰C. Nucleosides were then separated and quantified at the Duke Molecular 
Physiology Institute using UPLC-MS/MS as previously described [152], except acetic 
acid replaced formic acid in the mobile phase. 
 
Western Blots 
Whole cell lysates were prepared in whole cell extract buffer (WCEB: 50 mM Tris pH 
7.4, 150 mM NaCl, 5 mM EDTA, 0.1% SDS, and complete protease inhibitor (Promega, 
Madison, WI)). Equal amounts of protein (30-50 μg) were electrophoresed on a mini-
PROTEAN any KD acrylamide gel (Bio-Rad Laboratories, Hercules, CA) and 
transferred to Hybond ECL nitrocellulose (GE Healthcare, Chicago, IL).  Transfer was 
verified via Ponceau S staining then blot was blocked with 5% nonfat dry milk 
(LabScientific, Highlands, NJ) in Tris buffered saline with 0.1% Tween 20 (TBST) for 




at 4°C.  After washing extensively with TBST, blots were incubated for 1-2 hours at 
room temperature with appropriate anti-mouse (GE Healthcare),  anit-rabbit (GE 
Healthcare), or Rabbit anti-goat (Novus Biologicals, Littleton, CO), washed again with 
TBST, detected using Bio-Rad Clarity Western ECL Substrate (Bio-Rad Laboratories), 
and imaged via MYECL Imager (Thermo Scientific).   
 
Assaying newly transcribed mRNA 
Newly Transcribed mRNAs were isolated following pulse-labelling with 4-thiouracil. 
Cells were treated with 200 µM 4SU (Sigma-Aldrich) for 1 hour. RNA isolated via Trizol 
was biotinylated by labeling 50 µg RNA in a reaction mixture with 50 µl 10x Tris/EDTA 
buffer (TE), 100 µl 1mg/ml Biotin-HPDP (EZ-Link Biotin HPDP, Thermo Scientific, 
Waltham, MA) in dimethylformamide (DMF), and RNase free H2O brought to 400 µl. 
Mixture was incubated in the dark with rotation for 1.5 hours. Biotinylated RNA was 
extracted using an equal volume of chloroform/isoamyl alcohol (24:1) 2x in phase lock 
gel heavy tubes (5 Prime, Gaithersburg, MD) followed by RNA precipitation with 
isopropanol. RNA was heated to 65⁰C for ten minutes and placed immediately on ice. 
RNA was added to Dynabeads MyOne Streptavidin C1 (Thermo Fisher Scientific) that 
had been thoroughly washed and resuspended in 2X streptavidin binding buffer (2X TE, 
2M NaCl). The RNA bead mixture was incubated with rotation for 30 minutes. Beads 
were washed 5X with 65⁰C Wash Buffer (1XTE, 1M NaCl, 0.1% Tween20) and the 
supernatant was kept containing the non-labeled RNA. Three rounds of 100 mM 
dithiothreitol (DTT) elution followed by 1 round of TE eluted labeled RNA from the 





m6A mRNA Immunoprecipitation (MeRIP) 
m6A Ribonucleoprotein Immunoprecipitation reactions were performed by first isolating 
PolyA+ RNA from normoxic and hypoxic cells. Protein G Dynabeads (Thermo Fisher 
Scientific, Baltics UAB) were washed 3X in 1 mL of IPP buffer (10mM Tris-HCL pH7.4, 
150mM NaCl, 0.1% NP-40). 25 µl of beads required per IP. Anti-N6-methyladenosine 
mouse monoclonal antibody (EMD Millipore, Temecula, CA, MABE1006) was added to 
the beads (5 µg/IP) and brought up to 1mL with IPP buffer. Bead mixture was tumbled 
for 16 hours at 4⁰C. Beads were washed 5X with IPP buffer and 100ng of PolyA+ RNA 
was added to the beads along with 1mM DTT and RNase out. The mixture was brought 
up to 500 µl with IPP buffer. Bead mixture was tumbled at 4⁰C for 4 hours. Beads were 
washed 2X in IPP buffer, placed into a fresh tube, and washed 3X more in IPP buffer. 
m6A RNA was eluted off the beads by tumbling 2X with 125 µl of 2.5mg/mL N6-
Methyladenosine-5’-monophosphate sodium salt (CHEM-IMPEX INT’L INC., Wood 
Dale, IL). Supernatant was added to Trizol-LS followed by RNA isolation as per 
manufacture’s protocol. Final RNA sample was brought up in 10 µl of water. 
 
PCR for MeRIP 
Reverse transcription was performed on 10 µl m6A PolyA+ RNA from the MeRIP with 
the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA).  After diluting 
cDNA two-fold, quantitative real-time PCR was performed using a Roche Lightcycler 96 
with Fast Start Essential DNA Green (Roche Diagnostics Corporation, Indianapolis, IN) 




was verified to be over 95% for all primer sets used.  Quantification of mRNA from the 
MeRIP was carried out via ΔCT analysis against non-immunoprecipitated input RNA. All 
real-time PCR primer sets were designed so the products would span at least one intron 
(>1kb when possible), and amplification of a single product was confirmed by agarose 
gel visualization and/or melting curve analysis. 
 
siRNA Transfections  
Either a negative siRNA (Silencer; Life Technologies, Carlsbad, CA) or HIF-1α and HIF-
2α siRNAs (Silencer; Life Technologies,) transfected together using Lipofectamine RNAi 
Max 54 µl/plate as per manufacturer’s protocol (Life Technologies) using 180 pM 
siRNA/10 cm dish. Cells were incubated for 72 hours post-transfection with the last 24 
hours in either normoxic or hypoxic conditions.  
 
Plasmid Transfections 
Either a negative control plasmid shRNA scramble control, Alkbh5 psi-U6 shRNA 
construct (GeneCopoeia, Rockville, MD) or a Mettl3 and Mettl14 flag tagged construct 
given by Dr. Jing Crystal Zhao [13] was transiently transfected in immortalized and 
oncogenically transformed HMEC cells using Lipofectamine 2000 (Life Technologies). 
Cells were incubated for 48 hours post-transfection before scratch assays. 
 
Scratch Assays 
Cells were cultured in 6 well plates (USA Scientific) with MEBM supplemented media as 




8 hours prior to the scratch. A scratch was made with a p200 pipette tip (USA Scientific) 
and media was removed and cell washed with Dulbecco’s Phosphate Buffered Saline 
(DPBS) (Corning) and fresh serum free MEBM supplemented media added. Wound 
healing was measured at 24 hours post-scratch.  
 
Invasion Assays 
100µl of a 1/3 matrigel membrane matrix (Corning) diluted in 0.01M Tris pH8, and 0.7% 
NaCl was layered in a 6.5 mm Transwell with 8.0µM Polycarbonate membrane insert 
(Corning) and incubated for 6 hours in 37⁰C. 1x106 Cells were resuspended in 200µl 
serum free media and plated on the membrane. 600µl of media with serum was added 
to the lower chamber cells were incubated for 24 hours. Invading cells were fixed with 









Hs_HIF1A_5 S102664053, Qiagen 
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siHIF-2α 
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Gene Forward (5'-3') Reverse (5'-3') 
Dusp1 CAACCACAAGGCAGACATCA CAGTGGACAAACACCCTTCC 
eEF1A1 CGGTCTCAGAACTGTTTGTTTC AAACCAAAGTGGTCCACAAA 
Glut1 TATCGTCAACACGGCCTTCACTGT CACAAAGCCAAAGATGGCCACGAT 
Jun TTCTATGACGATGCCCTCAAC TCAGGGTCATGCTCTGTTTC 
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The work outlined in this dissertation describes unique functions for the mRNA 
modification N6-methyladenosine in hypoxia and breast cancer. Protein expression 
through translational regulation has been well studied in these and other similar 
systems. While understanding translational regulation has been useful, many protein 
expression phenomena in hypoxia and cancer have gone unexplained. Recently, 
research in these fields have started investigating post-transcriptional regulation in 
hypoxia and cancers, and in doing so have focused heavily on RBP and microRNAs 
that may alter the fate of the mRNA. The findings in this report indicate that an mRNA 
modification can also alter the fate of mRNAs and lead to changes in phenotype in a cell 
based model.  
Post-Transcriptional regulation of mRNAs in hypoxia 
 Post-transcriptional regulation of mRNAs can be altered in response to changing 
cellular environments. Hypoxia is one such environment that causes global cellular 
changes including overall decreases in general translation efficiency. A hypoxic cellular 
environment leads to the discontinuation of transcription and translation of many 
mRNAs and proteins resulting in the reduction of protein expression. However, it is 
interesting that transcription and translation of some mRNAs continue. Because hypoxia 
is important for embryonic development, tumor formation, and other situations where 
low oxygen occurs, it is necessary to understand how this hypoxic regulation of protein 
expression occurs. As stated before, past research has discovered that HIF plays a 
large role in transcriptional regulation in hypoxia, and translational regulation in hypoxia 
is achieved through phosphorylation of eIF2α slowing the recruitment of ribosomes to 




transcriptional regulation of hypoxic mRNA has been understudied. While in normoxic 
conditions RNA-binding proteins and micro-RNAs have been identified as important 
factors in post-transcriptional regulation, determining the specific RBP’s or micro-RNAs 
that may play a role in each specific cellular condition has been difficult. One 
explanation for these difficulties is the large number of RBPs and lack of knowledge of 
the consensus sequence or sequence specificity for these RBPs.  
In this report, our focus has been on the mRNA modification m6A which only 
occurs within a specific consensus sequence. Only a limited number of RBPs can 
interact with this consensus sequence, and only a few RBP’s binding potential are 
affected by the secondary structure changes caused by the m6A modification. In fact, a 
recent report determined many of the RBPs that are affected by the modification [166]. 
Based on this report, we can focus our attention on these specific RBPs to determine 
which one stabilizes mRNA through m6A in hypoxia as well as which RBPs have roles 
in other cellular conditions.  Because of this, some of the previously discussed 
difficulties can now be addressed when studying the effects of the m6A mRNA 
modification on post-transcriptional regulation. While not all post-transcriptional 
regulation processes will be affected by RNA modifications, understanding the effects of 
mRNA modifications on mRNA may lead to a better path for studying post-
transcriptional regulation in hypoxia and other cell stresses  
Consensus sequence of m6A methylation 
As stated earlier, m6A methylation in mRNA occurs at a DRACH consensus 
sequence primarily near both start and stop codons as well as a few sites in the coding 




methylated [167]. On average, each mRNA contains three actual m6A residues [61]. 
However, as one might imagine, not all consensus sequences are methylated at one 
given time. It seems possible, and likely, that the specific sites which are methylated 
may change in response to the cellular environment. It is possible that under hypoxic 
conditions, m6A sites switch from one consensus sequence to another. These potential 
switches in m6A sites could help explain the increase in m6A in hypoxic conditions. 
Perhaps m6A switches from a site located near a stop codon to a site in the middle of 
the coding sequence. This site switching of m6A might lead to switches in the RNA 
binding proteins that can bind the mRNA and may lead to differences in the fate of the 
mRNA. For example, this may cause m6A sites to be bound by YTHDF2 leading to 
degradation of the RNA, or it may switch sites to be bound by an RBP increasing mRNA 
stability. It would be possible to test the potential site switching through RNA 
sequencing methods.  
For example, MeRIP sequencing protocols as well as other RNA sequencing 
protocols use sequencing reads of fragmented RNA which is mapped back to the 
fragment’s parent RNA. This method would also allow us to determine which specific 
fragments of RNA are methylated in certain conditions. We could look at RNA from 
normoxic and hypoxic conditions to determine if there is a shift in the m6A landscape. 
For example, if we see m6A methylation in some targets mostly in the 3` end in normal 
conditions, but shift to the 5` end in hypoxic conditions we could conclude that hypoxia 
causes a shift in methylation sites. This type of experiment could allow us to determine 
the regulation of m6A methylation in hypoxia and other cellular conditions, and could 




methylation sites would lead to different RBP binding allowing for different effects of 
m6A methylation. 
m6A methylation dynamics 
 The results in this report show that m6A methylation levels change in response to 
a cellular stress condition. Based on these data we might conclude that m6A 
methylation is dynamically altered in response to hypoxia. However, recent reports have 
suggested that m6A may not be dynamic [21, 168]. In order to reconcile our findings 
with these reports, we must first define what each of us means by m6A dynamics. In the 
other report from the Darnell lab, they show that m6A levels do not change once pre-
mRNA is methylated and enters the cytoplasm. They show that the sites that are 
methylated in the nucleus are still methylated and are the only methylated sites in the 
cytoplasm. This data suggests that both the demethylases and methyltransferase do not 
function in the cytoplasm.  
This is not the same criteria that was used when we concluded that methylation 
is dynamically altered in response to hypoxia. We simply mean that m6A methylation is 
different in one condition compared to another. Still, it is possible that in hypoxic 
conditions, methylation does not change from its pre-mRNA stage to mature 
cytoplasmic mRNA.  However, my results also do not rule out the possibility that this is 
occurring. In fact, the report suggesting that m6A methylation is not dynamic only 
measures m6A levels in one cell type and in one cellular condition. We might expect 
that cells continuing to grow in long-standing normal conditions might not have a need 




types and other cell conditions, like hypoxia, methylation may change from nuclear to 
cytoplasmic mRNA.  
In order to test this in hypoxia, we would need to run MeRIP sequencing on 
nuclear and cytoplasmic mRNA from both normoxic and hypoxic conditions. However, 
we could also test the possibility of m6A dynamics (by Darnell’s definition) in any 
condition by determining if methylation or demethylation of mRNA can occur in the 
cytoplasm. I believe that these types of questions can be answered by future students in 
Dr. Mansfield’s lab.  
The effect of m6A methylation on RNA stability 
A major focus of the Mansfield lab is the effect of hypoxia on post-transcriptional 
regulation. Originally, Dr. Mansfield and others found that hypoxia increased the stability 
of a subset of mRNAs [124], and set out to find an RNA binding protein that might 
facilitate the increases in RNA stability. Around this time, it was reported that the m6A 
modification caused a decrease in mRNA stability [6, 9]. For this reason, I decided to 
investigate m6A in hypoxia and determine if it played a role in the increased stability of 
mRNAs in hypoxia. Our initial hypothesis was that m6A levels would decrease in 
hypoxia leading to an increase in mRNA stability. However, as seen in this dissertation, 
hypoxia led to an increase in m6A methylation in HEK-293T cells (Figure 2.1) as well as 
immortalized and oncogenically transformed HMEC cells (Figure 4.1). Originally, this 
increase in m6A made little sense as m6A has been shown to decrease mRNA stability 
rather than increase mRNA stability as was seen in hypoxic conditions. However, we 
tested the effect of the m6A modification on mRNA stability in hypoxia and found that 




have shown the m6A modification leads to mRNA degradation whereas we have shown 













Figure 4.1 Model of m6A in hypoxia 
One percent oxygen hypoxic stress leads to an increase in m6A levels in HEK-293T 
cells. This increase of m6A in hypoxia directly leads to stabilization of mRNA. 
Ultimately, this stabilization of mRNA led to quicker recovery after recovery from 




discrepancies that are worth investigating in the future.  
As stated previously, methylated RNA can be bound by a number of different 
RBPs, and these RBPs all have different functions. It is possible that in other systems, 
methylated mRNA is bound in majority by YTHDF2 which leads to degradation of 
mRNA, but in hypoxia a different RBP binds leading to mRNA stability. We attempted to 
observe any differences in m6A mRNA binding of RBPs including YTHDF2, YTHDF1, 
and YTHDC1. Unfortunately, we never were able to obtain any conclusive data. 
However, even if the m6A recognizing RBP were to change in hypoxic conditions, we 
must still ask ourselves why this might be occurring. Protein expression was measured 
and no differences in any of the m6A binding proteins were observed. It is also possible 
that the m6A binding proteins can be sequestered or activated in certain conditions. 
Additionally, it is possible that in hypoxic conditions, sites of m6A methylation were 
altered, as described in the previous paragraph, leading to differential outcomes in RBP 
competition.  
 The effect of m6A methylation on RNA stability in hypoxia may also have 
nothing to do with the currently identified m6A RBPs. m6A methylation has been shown 
to alter the secondary structure of mRNA [60]. It has also been found that this alteration 
of mRNA secondary structure has allowed additional RBPs to interact with the mRNA 
[58, 59]. It is possible that increased m6A methylation in hypoxia may lead to changes 
in the mRNA secondary structure which may attract additional RBPs that aid in mRNA 
stability, while repelling RBPs that lead to mRNA degradation. 
m6A methylation of mRNA can decrease the stability of mRNA as shown by 




is most likely able to regulate mRNA in both of these contradictory ways because of its 
effect on RNA secondary structure and recruitment of RBPs as described above. 
Overall, this would suggest that mRNA methylation is needed for fine tuning of protein 
expression in many cellular conditions.  
m6A methylation in Breast Cancer 
 The ultimate goal of this project was to determine if a post-transcriptional 
regulation process had a phenotypic effect on breast cancer. We used a genetically 
defined breast cancer progression model developed by our collaborators in Jack 
Keene’s lab at Duke University. In this model, m6A methylation decreases as cells 
progress to a cancerous phenotype, but m6A levels were increased back to primary cell 
like levels in hypoxia (Figure 4.2). These changes in m6A levels bring up numerous 
questions about the impact of m6A methylation on cellular phenotype. Firstly, why does 
m6A methylation decrease during breast cancer progression? Is the decrease in m6A 
because of the progression in the cancer phenotype, or does the decrease in m6A aid 
in the cancer phenotype? Based on our data in Chapter 3, it appears that the decrease 
in m6A methylation does not aid in the progression of the cancer phenotype as 
increasing m6A in the transformed cells further stimulates the cancer phenotype. 
However, due to technical issues we were never able to manipulate m6A in the primary 
cells through transient transfection methods. As these cells have shown they can be 
manipulated through a pCL retroviral vector system [163], it may be possible to 
manipulate m6A through this same system. We could then test if overexpressing or 
knocking down m6A in the primary cells led to a cancer like phenotype. Based on ours 
















Figure 4.2 m6A methylation in a breast cancer progression model 
m6A levels decrease in immortalized and transformed HMEC cells. This decrease in 
m6A is due to a decrease in the methyltransferase Mettl3 and an increase in the 
demethylase ALKBH5. m6A levels in the immortalized and transformed lines then 






to a cancer like phenotype, as we and others have seen that m6A itself does not lead to 
cell progression, but rather seems to fine-tune the current process already in place. 
The second question we must ask is why does m6A levels increase in hypoxic 
conditions. In fact, this increase in m6A directly contradicts previous reports that show 
m6A methylation decrease in breast cancer stem cells in hypoxic conditions [15]. There 
are many reasons that might suggest why our data is contradictory to theirs. First, their 
report measured m6A methylation in total RNA rather than mRNA. In fact, I would find it 
difficult to make any conclusions about m6A in mRNA from their report given that mRNA 
makes up a small percentage of total RNA. Additionally, they did not measure m6A 
methylation using LC-MS which has become the gold standard for measuring global 
m6A levels, but rather used an antibody-based colorimetric methylation quantification kit 
that is rather inexpensive and readily accessible but is still rarely used in the field due to 
poor results.   However, they did notice a decrease of m6A in a specific mRNA, Nanog, 
using the MeRIP technique. Unfortunately, we were not able to confirm these results in 
any of our cell types as Nanog was not expressed in the cell types used in our project. 
Based on these facts, there are many possibilities as to why our data is contradictory 
with this previous report, but we still must answer how m6A is increasing in hypoxic 
conditions in our model system.  
Based on our data (Figure 3.6), m6A methylation rates in newly transcribed 
RNAs were not increased in hypoxic conditions. Therefore, either m6A is dynamic in the 
cytoplasm (even though other reports suggest that m6A is not dynamic as I explained 
previously in this chapter) or there is simply a buildup of stabilized methylated mRNA as 




appears to be regulated by HIF as knockdown of HIF decreased m6A methylation in a 
number of specific mRNA targets. Interestingly, in the previous report that was 
mentioned earlier has conversely shown that HIF knockdown increased m6A levels in 
Nanog mRNA. Once again, these results could not be confirmed in our model as Nanog 
is not expressed, but it seems likely that HIF is regulating m6A methylation, but different 
mRNA messages are regulated in opposite ways. Overall, it appears that according to 
our data, m6A methylation is increased in hypoxic conditions due to a HIF-mediated 
response in which m6A methylated mRNAs are stabilized. 
Our data has also shown that m6A alone is able to phenotypically alter our 
transformed HMEC cells. Overexpressing the m6A methyltransferase or knocking down 
the demethylase ALKBH5 and thereby increasing m6A levels led to increased wound 
healing and invasion. Once again, the previous report showed that increased m6A 
levels through ALKBH5 knockdown impaired breast tumor formation. While we did not 
directly measure tumor formation, these two data sets again seem to be at odds. Keep 
in mind however, that our report, and this previous report are using two different 
models. While we are using a cancer progression model, this previous report used a 
breast cancer stem cell model. It seems likely that the m6A modification affects different 
stages of cells in opposing ways. Keep in mind, however, that m6A acted in contrasting 
ways in different stages of embryonic stem cells as described in chapter 1. In those 
reports, it appeared that m6A was simply fine-tuning the current cell stage rather than 
regulating progression of the stages. It is for this reason we need to investigate m6A 






The results from this dissertation project have aided the ever-growing m6A 
methylation and hypoxia fields in many ways. As stated before, previous reports had 
shown that m6A methylation led a decrease in mRNA stability. The work in this report 
proved that m6A methylation does not always lead to mRNA degradation, but rather 
may actually lead to increased mRNA stability depending on the situation. In addition, 
this report also revealed methods by which mRNA is stabilized under hypoxic 
conditions. It had been previously reported that hypoxia led to stabilization of a subset 
mRNAs, but these reports failed to conclusively find how these mRNAs were being 
stabilized. The data shown in this dissertation indicates that an increase in the m6A 
modification leads to stabilization of at least a handful of these specific mRNAs. This 
report also measured m6A methylation in a breast cancer cell progression model, and 
to my knowledge, is the first to show m6A levels decrease after progression from a 
normal primary cell to a cancer cell line in breast cancer or any other cancers. 
Excitingly, this project also determined that manipulation of the mRNA modification 
alone is enough to alter the phenotype of breast cancer through increased wound 
healing and invasion. Overall, my research has shown that m6A methylation does not 
have just one defined function in every cell condition, but rather fine-tunes protein 








 The importance of m6A methylation in many cellular processes is still not very 
well known. This field of study is still in its infancy, and I believe that there are many 
other avenues of focus for this project that will lead to many revealing results for the 
m6A field. Previously in this chapter I have described a few major questions in the field 
that deserve attention. I will summarize those potential directions for future projects as 
well as talk about a few others.  
 As stated above, the question of the m6A modification being dynamically 
regulated is very important to the m6A field right now, and I believe that hypoxia is the 
perfect model to answer this question. Using hypoxia, we may be able to determine if 
m6A levels can be altered in mature mRNA. In order to test this, it must first be 
established that methylation and demethylation can occur within the cytoplasm. 
Secondly, it must be determined if m6A methylation sites remain the same in nuclear in 
cytoplasmic cells when comparing cells grown in normal conditions to those in hypoxic 
conditions. In my opinion, it seems likely that m6A methylation is dynamic when cellular 
environments are changed.  
 Another important question that I think needs to be answered is which RBP is 
stabilizing m6A methylated mRNA in hypoxia. We know that YTHDF2 leads to 
degradation of m6A mRNA, but which RBP leads to stabilization? It is possible that an 
m6A binding protein or another RBP that binds due to the secondary structure 
rearrangements through the m6A modification may lead to mRNA stabilization. A recent 
paper has discovered a number of RBPs that the m6A modification attracts [166]. It 




stability through m6A. One would first have to determine which of these RBPs affects 
mRNA stability in hypoxia, and show a switch between its binding and a loss of 
YTHDF2 binding in hypoxia. I would propose that the hypoxic increase in m6A leads to 
secondary structure changes allowing for a non-m6A binding RBP to increase stability 
of the mRNA. It seems less likely that an m6A binding protein is able to have this affect 
as many of their functions are already known.  
 These previous two future directions projects are very mechanistic in nature. 
However, it is also important to continue investigating m6A methylation in breast cancer. 
I feel that it is necessary to repeat many of the findings in this report in other breast 
cancer types to fully understand m6A’s role in breast cancer. Additionally, it is 
interesting that increased m6A in the immortalized HMEC cell line does not lead to the 
same phenotype as increased m6A in the oncogenically transformed cell line. One 
benefit of this system is that we know that the only difference between these two cells is 
the activation of hRAS in the oncogenically transformed line. It is therefore quite 
possible that the increase in m6A is working in conjunction with RAS or one of its 
downstream effectors. A major question that needs to be answered is how increased 
m6A after RAS activation leads to increased wound healing and invasion. It seems 
possible that increased m6A levels in specific RAS regulated mRNAs involved in 
migration may lead to greater expression of these proteins. Additionally, it is very 
important to determine the effects of m6A in breast cancers in an animal model. While 
the results in the breast cancer model in this report is a great starting point, we can only 




 The projects I have outlined in this future directions section are, in my opinion, 
the most logical next steps in m6A research based on the results from my project. I 
believe the results I have obtained during these last 4 years in the Mansfield lab have 
influenced and impacted the RNA modification field and have provided a strong 
foundation for future investigations. It is my hope that the continuation of these lines of 
research will lead to valuable information that can someday be used to develop novel 
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